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1. Introduction 
 
 
 
 
 
1.1 The Interferon System 
 
Interferons (IFNs) are broadly expressed cytokines with potent antiviral and growth-
inhibitory effects, that constitute the first line of defense against viral infections. The IFN 
system includes cells that synthesize IFN in response to viral infection and cells that 
respond to IFN by establishing an antiviral state (1).  The IFN family includes two main 
classes of related cytokines: type 1 and type 2 IFNs (1, 2). There are many human type 1 
IFNs, which share considerable structural homology, including IFNα (which can be 
further divided into 13 different subtypes), IFNβ, IFNε, IFNκ and IFNω (1, 2). The genes 
encoding human type 1 IFNs are clustered on chromosome 9 (2). The common cell-
surface receptor on which all type 1 IFNs bind is known as the type 1 IFN receptor (1, 2). 
The type 1 IFN receptor is composed of two subunits, IFNAR1 and IFNAR2, which are 
associated with the Janus activated kinases (JAKs), JAK1 and TYK2 (Fig.1). In contrast 
to the type 1 IFNs, that are all clustered on chromosome 9, there is one type 2 IFN, IFNγ 
(1, 2) that is located on human chromosome 12. There is no marked structural homology 
between type 1 and 2 IFNs (1-4). The receptor which IFNγ binds to is known as the type 
2 IFN receptor (5). This receptor is also composed of two subunits called IFNGR1 and 
IFNGR2, which are associated with JAK1 and JAK2 (Fig1). Recently a new class of 
IFNs has emerged, the IFNλ 1,2 and 3, also known as interleukin 29, 28A and 28B. They 
display antiviral properties, but they are distinct from the type 1 and type 2 IFNs and bind 
to a different receptor, which is composed of two chains, IFNLR1 and IL-10Rb (6). The 
initial step in both type 1 and type 2 IFN mediated signaling is the activation of the 
receptor associated JAKs by dimerization of the receptor subunits, followed by 
autophosphorylation and activation of the associated JAKs. JAKs then activate the 
classical JAK-STAT (signal transducer and activator of transcription) - signaling 
pathways (Fig.1). But they also activate directly or indirectly several other downstream 
cascades. 
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1.2 The Jak-STAT signaling pathway 
 
 
1.2.1 Activation of the Jak-STAT pathway 
The first signaling pathway shown to be activated by IFNs was the JAK-STAT pathway. 
Discovered in the 1990s (7-10), this pathway provides a simple model for IFN-mediated 
signaling (Fig.1). The model involves rapid nuclear translocation and initiation of gene 
transcription by STATs that have been activated at the plasma membrane in response to 
JAK-mediated phosphorylation. This mechanism is required for the induction of many of 
the effects of IFNs.  The binding of IFNα or other type 1 IFNs to the type 1 IFN receptor 
results in the rapid autophosphorylation and activation of the receptor associated JAKs 
TYK2 and JAK1 (10), which in turn regulate the phosphorylation and activation of 
STATs (11, 12). STAT 1,2,3 and 5 are activated in response to type 1 IFNs (11-14). After 
phosphorylation by JAKs, the activated STATs form homo- or heterodimers that 
translocate to the nucleus to initiate transcription by binding specific sites in the 
promoters of IFN-stimulated genes (ISGs), that mediate various biological responses (3, 
11, 12). There are two different binding elements in the promoters of IFN-stimulated 
genes: IFN-stimulated response elements (ISREs) and IFN-γ-activated site (GAS) (4, 12, 
15). The complex, which binds to the ISRE is composed of the phosphorylated forms of 
STAT1 and STAT2, together with IRF9, which does not undergo tyrosine 
phosphorylation (11-13).  Other STAT complexes that are induced by type 1 IFN, 
including homodimers like STAT1-STAT1 or heterodimers like STAT1-STAT3, bind to 
the GAS element (4, 12, 13). Of the hundreds of known IFN-stimulated genes, some have 
only ISREs or only GAS elements, whereas others have both elements in their promoters 
(Fig.1). 
The transcription of type 2 IFN (IFN-γ)-dependent genes is regulated by GAS elements. 
After binding of IFNγ to the type 2 receptor, JAK1 and JAK2 are activated and regulate 
downstream phosphorylation of STAT1 on the tyrosine residue at position 701.  The 
phosphorylated STAT1 molecules form STAT1-STAT1 homodimers, which translocate 
to the nucleus and bind to GAS elements to induce transcription (16).  There is no 
formation of ISGF3 complexes in response to IFNγ and therefore no induction of genes 
that have only ISREs in their promoter (Fig.1). 
 
 
 
1.2.2 Negative Regulation of the Jak-STAT Pathway 
Negative regulation of the Jak-STAT pathway occurs at two different points in the 
signaling cascade: at the level of the Janus kinases and at the level of STATs. The 
suppressor of cytokine signaling (SOCS) family members, SOCS1 and SOCS3, inhibit 
the catalytic activity of Janus kinases and therefore they prevent the phosphorylation and 
activation of IFNα induced STATs (17).  A second inhibition occurs downstream of 
STAT1 activation by protein inhibitor of activated STAT1 (PIAS1). PIAS1 binds to 
STAT1 dimers and therefore prevents the binding of STAT1 dimers to the response 
elements in the promoter of target genes (18, 19). The binding of PIAS1 to STAT1 is 
regulated by methylation of STAT1 by protein arginine methyl transferase 1 (PRMT1) 
(20). Arginine methylation inhibits binding of PIAS1 to STAT1, whereas 
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hypomethylation of STAT1 enhances its association with PIAS1 and therefore prevents 
the binding of activated STAT1 to DNA. Recently it was shown that PIAS1 selectively 
regulates a subset of IFNγ- or IFNβ-inducible genes by interfering with the recruitment of 
STAT1 to the gene promoter. The DNA-binding affinity of STAT-binding sites present 
in the promoters of STAT1 target genes can influence the PIAS1 effect. PIAS1 has a 
more profound effect on genes containing weak STAT-binding sites (for example, Gbp1, 
Ly6e), than genes containing strong STAT1-binding site (for example, Irf1)(19).  
 
 
 
 
 
Fig.1: Interferon receptors and activation of JAK-STAT pathways by type 1 and type 2 interferons (21). 
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1.2.3 Viral Interference with the Jak-STAT pathway 
Both DNA and RNA viruses encode proteins that impair the activity of the Jak-STAT 
signaling pathway to inhibit the induction of an antiviral response. Multiple mechanisms 
appear to be involved in this inhibition. For example, poxviruses encode soluble IFN 
receptor homologues. These proteins are secreted from poxvirus-infected cells and bind 
IFNs, thereby preventing them from acting through their natural receptors to elicit an 
antiviral response (22). The E1A protein of the adenovirus inhibits the DNA binding 
activity of ISGF-3 (23). Also the sendai virus, a paramyxovirus virus, that replicates in 
the cytoplasm of the host cell, inhibits the IFN-induced antiviral response by interfering 
with the transcriptional activation of IFN-inducible genes (24) to prevent the 
establishment of an antiviral state. The herpesvirus varicella-zoster virus (VZV) inhibits 
the expression of STAT-1 and Jak-2 (25) and another herpesvirus, the cytomegalovirus 
(CMV) inhibits the IFN signaling by decreasing the level of Jak-1 due to enhanced 
protein degradation (26). Several RNA viruses encode gene products that inhibit Jak-
STAT signaling. For example, infection with simian virus 5 or mumps virus leads to an 
increased proteosome-mediated degradation of STAT1 (27), whereas infection with 
parainfluenza virus type 2 leads to degradation of STAT-2 (28). The hepatitis C virus 
inhibits the IFN signaling by blocking methylation of STAT1. The expression of HCV 
proteins in liver cells of transgenic mice reduced STAT1 methylation and consequently 
increased association of STAT1 with PIAS1. Importantly, reduced methylation and 
increased PIAS1-STAT1 binding was also observed in liver biopsies from patients with 
chronic hepatitis C. There is evidence that protein phosphatase 2A is involved in 
mediating this effect by inhibiting the methylation of STAT1 through PRMT1: first, 
PP2A was found to be overexpressed in HCV transgenic mice and in liver biopsies from 
patients with chronic hepatitis C; second, Huh7 cell stably expressing the catalytically 
active HA-PP2Ac have hypomethylated STAT1 in the absence of any HCV proteins; and 
third, inhibition of PP2A with okadaic acid partially restores methylation of STAT1 (29, 
30).  
 
 
 
1.3 Viral hepatitis 
 
1.3.1 Hepatitis C  
Hepatitis C virus (HCV) infection is a major cause of chronic hepatitis, liver cirrhosis, 
and hepatocellular carcinoma (HCC) worldwide. Currently about 170 million people 
world wide (3%) are infected with HCV. Acute hepatitis C is usually asymptomatic but 
leads to chronic infection in 50-80% of cases. Patients with chronic HCV are at high risk 
to develop liver cirrhosis and HCC. The mechanisms underlying viral persistence and 
pathogenesis are poorly understood. So far no protective vaccine is available and 
therapeutic options are limited. The currently used therapy is pegylated interferon alpha 
(PEG-IFNα) combined with ribavirin. Only approximately 50% of treated patients 
develop a sustained virologic response (SVR, no HCV detectable in the blood six months 
after the end of the treatment) after treatment.   The cause of treatment failure in non-
responders is not fully understood, but recently viral interference with the Jak-STAT 
pathway has emerged as possible cause (29, 30).  
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HCV was identified more than a decade ago (31). Investigation of the replication cycle 
has been limited by the low viral titers found in sera and livers of infected individuals and 
the lack of an efficient cell culture system or small animal model permissive for HCV. 
However, considerable progress has been made using heterologous expression systems, 
functional cDNA clones (32) and subgenomic replicon systems (33). These systems use 
self-replicating subgenomic viral RNAs. But replicons only recapitulate the intracellular 
life cycle of HCV, they do not produce infectious virus. However, an HCV isolate from a 
Japanese patient with fulminant HCV infection could be identified, that, for unknown 
reasons, replicates in a human hepatoma cell line (34, 35) and cells releases virus 
particles that are infectious. This in vitro system provides new possibilities to study the 
HCV life cycle and to develop novel antiviral drugs.  
HCV belongs to the genus Hepacivirus within the Flaviviridae family. The 9.6 kb plus-
strand RNA genome contains a 5` noncoding region (5`NCR), a long open reading frame 
encoding a polyprotein precursor of about 3000 amino acids, and a 3`NCR. The 5`NCR is 
highly conserved and contains an internal ribosomal entry site (IRES), that is essential for 
cap-independent translation of viral RNA (36). The polyprotein precursor is co- and 
posttranslationally processed by cellular and viral proteases into structural and non-
structural proteins (Fig.2). The structural proteins include the core protein that forms the 
viral nucleocapsid and the envelope glycoproteins E1 and E2 (37). The nonstructural 
proteins include the NS2-3 autoprotease responsible for the cleavage of the polyprotein 
precursor at the NS2/NS3 junction, the NS3 serine protease (a NTPase/RNA helicase), 
the NS4A, that function as a cofactor for the NS3 serine protease, the NS4B involved in 
the formation of the membranous web, the NS5A and the NS5B RNA-dependent RNA 
polymerase (RdRp), the key enzyme responsible for replication (38-41).  
 
 
 
 
Fig. 2: Schematic representation of the HCV genome with the sructural proteins C, E1 and E2 and the non-
structural proteins (42). Core (C) forms the nucleocapsid, E1 and E2 are the envelope glycoproteins, p7 
probably forms an ion channnel involved in some step of virus production; NS2 is a cysteine protease, NS3 
forms a stable comples with NS4A creating the viral serine-type protease whereas the C terminal domain 
contains nucleotide triphosphate (NTPase) and helicase activity, NS4B can induce the formation of 
intracellular membrane vesicles presumably forming the scaffold of the viral replication complex; 
phosphoprotein NS5A is a RNA-binding replication factor; and NS5B is the RNA-dependent RNA 
polymerase (RdRp). 
 
 
The life cycle of HCV starts with the binding to cell surface receptor CD81(43) on the 
membrane of the hepatocyte and with internalization into the host cell. After this first 
initial step, the cytoplasmic release and uncoating of the viral RNA genome follows. 
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Afterwards IRES-mediated translation, polyprotein processing and RNA replication start. 
The last steps are packaging, assembly and virion maturation, followed by virion release 
from the host cell (44) 
 
 
 
1.3.2 Hepatitis B 
Hepatitis B virus (HBV) is a member of the Hepadnaviridae (hepatotropic DNA virus) 
family. Hepadnaviruses display a strong preference for infecting liver cells, but small 
amounts of viral DNA can also be found in kidney, pancreas and monocuclear cells (45, 
46). HBV virions are double-shelled particles containing an outer lipoprotein envelope 
composed of three related envelope glycoproteins (or surface antigens) and within the 
envelope the viral nucleocapsid or core (47). The core contains the viral genome, a 
relaxed-circular, partially duplex DNA of 3.2 kb and a polymerase, responsible for the 
synthesis of viral DNA in infected cells (48). Additionally to virions, cells infected with 
HBV produce filamentous and spherical particles. These HBsAg particles contain only 
envelope glycoproteins and host-derived lipids (49, 50).  The HBV genome consists of 
four open reading frames. The presurface-surface region encodes the three viral surface 
antigens (S protein known as HBsAg, M protein and L protein) by differential initiation 
of translation (47, 49-51). The preC-C region encodes the hepatitis B core antigen 
(HBcAg) and the hepatitis B e antigen (HBeAg)(47). HBeAg is secreted into the blood 
(52), and so far its function is unclear. The P coding region encodes the viral polymerase, 
an enzyme involved in DNA synthesis and RNA encapsidation. Finally the X protein 
(HBx) is transcribed from the X open reading frame. This protein is required for the in 
vivo replication and for the spread of the virus (53).  
The viral replication cycle starts with the binding of HBV virions to cell-surface 
receptors, followed by membrane fusion. The free core is then transported across the 
cytosol to the nucleus. There the HBV genome is converted to a covalently closed 
circular form (cccDNA) (54), serving as transcriptional template for host RNA 
polymerase 2. Afterwards the viral RNA is translocated to the cytoplasm, where its 
translation yields the viral proteins. The following step is the assembly of the 
nucleocapsids in the cytosol. During this process a single molecule of genomic RNA is 
incorporated into the viral core and the reverse transcription starts (55, 56). Most of the 
cores, bearing the mature genome acquire lipoprotein envelopes containing the viral L, M 
and S surface antigens and are then exported from the cell. The HBV replication cycle is 
not directly cytotoxic to cells, but the host immune responses to viral antigens displayed 
on infected hepatocytes are the principal cause of liver damage (57). 
Primary HBV infection in nonimmune hosts can be either symptomatic or asymptomatic. 
Most of the primary infections in adults are self-limited, with clearance of the virus from 
blood and liver (58, 59). However some primary infections in healthy adults (less than 10 
percent) develop into persistent infections, which can be symptomatic or asymptomatic. 
Patients with normal serum aminotransferase levels and normal findings on liver biopsy 
are called asymptomatic chronic HBV carriers. Those patients with abnormal liver 
function tests and pathological findings on liver biopsy have chronic hepatitis B (CHB). 
Worldwide more than 350 million people are chronically infected with HBV (60, 61).  
These patients are at risk to develop liver cirrhosis and HCC. Approved treatments for 
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chronic hepatitis B include nucleos(t)ide analogues like lamivudine and adefovir, or 
interferon α (IFNα), recently in pegylated form (PegIFNα) (61).  However, over 60 
percent of patients do not respond to the PegIFNα treatment and continue to suffer from 
chronic active infection. The molecular mechanisms causing the ineffectiveness of IFNα 
treatment in chronic hepatitis B are not known so far. 
 
 
 
 
1.4 Structure and function of protein phosphatase 2A 
 
Reversible protein phosphorylation is an essential regulatory mechanism in many cellular 
processes, and cells use this post-translational modification to change the properties 
(activity, cellular localization, etc.) of proteins involved in specific pathways. One 
important protein phosphatase in cells is the protein phosphatase type 2A (PP2A). PP2A 
accounts for as much as 1 percent of total cellular proteins and for the major portion of 
serine/threonine phosphatase activity in most tissue and cells (62). Deletion of the gene-
encoding PP2A catalytic subunit is lethal in mice, showing the essential role of PP2A 
(63). PP2A dephosphorylates a myriad of substrates, and is involved in the regulation of 
many cellular activities including cell cycle regulation, cell morphology, development, 
signal transduction, translation, apoptosis, and stress response (64). An approximately 36 
kD catalytic subunit (PP2Ac), that is associated with a 65 kD scaffolding subunit called 
A or PR65, which modulates the enzymatic activity of the catalytic subunit, build the 
core enzyme of PP2A (65). Distinct classes of regulatory B subunits can bind to AC to 
form a wide variety of heterotrimeric complexes (Fig.3). The expression of PP2A is 
tightly regulated (66), but downregulation of PP2Ac has been found during all-trans-
retinoic acid induced differentiation of HL-60 cells (67) or during peroxisome 
proliferator-activated receptor-γ induced adipocyte differentiation (68). On the other side, 
upregulation of PP2Ac was found in response to colony-stimulating factor 1 (69). 
Recently it was shown, that the expression of HCV proteins in livers of transgenic mice 
induce an upregulation of PP2Ac, that was also observed in liver biopsies from patients 
with chronic HCV infection(30).  
 
 
Fig.3: Structure of PP2A holoenzyme. 
The core enzyme is a dimer, consisting of the 36kDa catalytic subunit (C) and the regulatory subunit of 
molecular mass 65kDa, termed PR65 or A subunit (A). A and C are encoded by two genes (α and β). A 
third regulatory B subunit can be associated with this core structure. At present, four different families of B 
subunits (B, B`, B`` and B```) have been identified (64). 
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1.5 Protein Arginine Methyltransferase 1 (PRMT1) 
 
There is strong evidence that PP2A inhibits PRMT1 and therefore leads to 
hypomethylation of STAT1. Methylation of STAT1 displays the third important 
posttranslational modification beside tyrosine and serine phosphorylation that regulates 
STAT1 mediated transcriptional activation of IFNα target genes. Methylation of arginine 
31 of STAT1 is catalyzed by PRMT1 and inhibits the binding of PIAS1 to STAT1 (20). 
PRMT1 is a ubiquitously expressed protein arginine methyltransferase type 1. The type 1 
enzymes recognize substrates containing GAR motifs (glycine and arginine-rich motifs), 
and the methylation occurs in two steps with an intermediate monoarginine, followed by 
an asymmetric dimethylarginine. Substrates of PRMT1are involved in transcriptional 
regulation, signal transduction and DNA repair (70). Methylation of histone H4 through 
PRMT1 for example leads to a change in chromatin conformation and therefore to a 
change in transcription. Interestingly, PRMT1 is also responsible for arginine methylation 
of HCV helicase NS3 on arginine 1493 (71). Furthermore mutational analysis showed, 
that this arginine together with arginine 1490 is essential for the enzymatic activity of 
NS3 helicase (72). However, the consequences of this possttranslational modification of 
NS3 and the possible effect of PP2A on the methylation of NS3 have not been 
investigated. 
 
 
 
 
1.6 The ER stress response 
 
The endoplasmatic reticulum (ER) is the first organell in the secretory pathway 
responsible for the synthesis, modification and delivery of proteins to their target sites. In 
the ER, proteins fold into their native conformation and undergo post-translational 
modifications like asparagine-linked glycosylation and the formation of intra-or 
intermolecular disulfid bonds (73-75). Only correctly folded proteins are exported to the 
Golgi complex, while malfolded proteins are targeted for degradation (76). Folding of 
proteins requires a complex ER-resident protein folding machinery consisting of three 
classes of proteins: foldases, molecular chaperones and the lectins calnexin, calreticulin 
and ER degradation-enhancing α-mannosidase-like protein (EDEM). Foldases are 
enzymes that catalyze steps in protein folding (77, 78). Molecular chaperones facilitate 
protein folding by shielding unfolded regions from surrounding proteins without 
enhancing the rate of protein folding. One prominent chaperone is BiP (binding protein or 
glucose regulated protein GRP78). The lectins play an important role in the quality-
control machinery of the ER (79, 80).  In several situations the demand on the ER-
resident protein folding machinery exceeds its capacity, e.g. during viral infection (81, 
82). As a result the ER is overloaded with native, unfolded proteins, which induces an ER 
stress response, called the unfolded protein response (UPR) (83). There are two adaptive 
mechanisms to bring the folding capacity of the ER to its normal physiological state: 
increasing the folding capacity through induction of ER-resident molecular chaperones 
and foldases and decreasing the biosynthetic load of the ER through down-regulation of 
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protein synthesis on a transcriptional and translational level (84, 85) as well as increased 
clearance of unfolded proteins from the ER through ER associated degradation 
(ERAD)(86, 87). If these mechanisms do not solve the stress situation, apoptosis is 
initiated in higher eukaryotic organisms to eliminate unhealthy or infected cells (88).  
Three transmembrane proteins transduce the unfolded protein signal across the 
endoplasmic reticulum membrane: inositol requiring 1 (IRE1), double-stranded RNA-
activated protein kinase (PKR)-like endoplasmic reticulum kinase (PERK) and activating 
transcription factor 6 (ATF6) (Fig.4).  In an inactive state the luminal domains of these 
three proteins are associated with BiP (89, 90). During ER stress, BiP is competitively 
titrated from the luminal domains by the huge excess of unfolded proteins in the ER 
lumen, resulting in activation of these proximal signal transducers. 
ATF6 translocates to the Golgi complex after being released from BiP and is cleaved in 
the Golgi by site-1 and site-2 proteases (S1P, S2P). These proteolytic reactions release 
the cytosolic N-terminal portion of ATF6 encoding a basic leucine zipper (bZIP) 
transcription factor (91-93). ATF6 binds to the ATF/CRE element (94) and to the ER 
stress response elements 1 and 2  (ERSE-1/2)(95, 96). Important targets regulated by 
ATF6 are BiP/GRP78, XBP-1 and CHOP (96) (Fig.4). 
The IRE1 pathway starts with IRE1 oligomerization after dissociation from BiP, followed 
by activation of the RNase domain of IRE1 through autophosphorylation. The substrate 
for the endoribonuclease is the mRNA for the bZIP transcription factor XBP-1 (97-99). 
XBP-1 splicing introduces a frame-shift and an alternative C-terminus with increased 
transcriptional activation potential. XBP-1 controls a subset of ER-resident molecular 
chaperones 149 (100). 
PERK is activated by release of BiP from its ER luminal domain. PERK then 
oligomerizes and phosphorylates its substrate eIF2α. Phosphorylation of eIF2α by PERK 
shuts-off general translation (29). During inhibition of translation, short-lived proteins 
like cyclin D1 are cleared from the cell. Loss of cyclin D1 during ER stress arrests 
mammalian cells in G1-phase (101). However the translation of proteins is not 
completely inhibited. There are some selected mRNAs, which are preferentially 
translated. One of these mRNAs is the mRNA of ATF4 (102), which regulates as a 
transcription factor the transcription of CHOP and GADD34 (103). 
Another important function of the ER beside the synthesis, modification and delivery of 
proteins to their target sites is the storage of Ca2+. In mammalian cells the ER is the major 
site for Ca2+ storage. ER luminal Ca2+ concentrations reach 5 mM, compared to 0.1 mM 
in the cytosol (105). The majority of the ER-resident molecular chaperones and foldases 
are vigorous Ca2+ binding proteins. Any change of the ER Ca2+ pool affects the folding 
capacity and activity of these enzymes (106). 
It is well known that viral infection of a cell can induce ER stress. As a processing plant 
for folding and post-translational modifications of proteins, the ER is an essential 
organelle for viral replication and maturation. In the course of productive infection, a 
large amount of viral proteins are synthesized in infected cells, where unfolded or 
misfolded proteins activate the ER stress response.  For HCV it has been published that 
the expression of envelope E1 and E2 proteins (107, 108), the expression of HCV core 
proteins (109) or the transfection of subgenomic replicons (110) induce an ER stress 
response. But there are also publications reporting that HCV disrupts part of the ER stress 
response (111, 112) 
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Fig.4: The unfolded protein response.  
Upon aggregation of unfolded proteins, BiP dissociates from the three endoplasmic reticulum (ER) stress 
receptors, pancreatic ER kinase (PKR)-like ER kinase (PERK), activating transcription factor 6 (ATF6) and 
inositol-requiring enzyme 1 (IRE1), allowing their activation. The activation of the receptors occurs 
sequentially, with PERK being the first, rapidly followed by ATF6, whereas IRE1 is activated last (104). 
The phosphorylation of eIF2 by PERK leads to a general inhibition of translation, but selected mRNAs, 
like the transcription factor ATF4 mRNA, are more efficiently translated. ATF4 initiate the expression of a 
subset of ER stress response genes. After translocation to the Golgi and cleaveage, ATF6 function as an 
active transcription factor and induces also ER stress response genes. Activated IRE1 splices the 
cytoplasmic XBP1 mRNA, and an active transcription factor is translated from this spliced mRNA. 
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2. Aims of the study 
 
The overall aim of the studies presented in this thesis, was to investigate the molecular 
mechanisms induced by HCV respectively HBV to inhibit IFNα signaling in cells 
 
 
 
2.1 Aim 1 
 
The first project investigated the functional consequences of NS3 methylation, the HCV 
helicase. Furthermore, the regulation of PRMT1 by PP2A was studied, because PRMT1 
is responsible for NS3 methylation and PP2A is upregulated by HCV. 
 
 
2.2 Aim 2 
 
Based on our current model of HCV interference with IFNα signaling (Fig.5), the second 
project explored if the HCV induced STAT1 hypomethylation could be corrected by 
treatment of cells with the methylgroup donor AdoMet and betaine. 
 
 
 
 
Fig.5: Interference of HCV with IFNα signaling: current working model. 
The expression of HCV proteins induces the upregulation of PP2A. Increased PP2A levels inhibit the 
activity of PRMT1, leading to hypomethylation of STAT1. The hypomethylated STAT1 is bound by 
PIAS1 and therefore STAT1 dimers, even when phosphorylated upon IFNα treatment, cannot bind 
anymore to the promoter of IFN target genes.  
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2.3 Aim 3 
 
The third aim was to investigate the IFNα signaling in HBV infection. As mentioned 
above, only 40% of chronic hepatitis B patients treated with IFNα shows clearance of the 
virus, and it is still unknown what mechanisms are involved in HBV resistance to IFNα 
treatment. Despite the fact, that HBV and HCV are completely unrelated viruses, we 
hypothesize that to establish resistant infection HBV could inhibit IFNα signaling using 
similar mechanisms than HCV. 
 
 
 
 
2.4 Aim 4 
 
The fourth project investigated the molecular mechanisms of PP2A upregulation in cells 
expressing HCV and HBV proteins. 
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Abstract 
Interferon alpha (IFNα) and pegylated IFNα (pegIFNα) are used for the treatment of 
chronic hepatitis B (CHB). Unfortunately, only a minority of patients can be cured. The 
mechanisms responsible for HBV resistance to (peg)IFNα treatment are not known. 
PegIFNα is also used to treat patients with chronic hepatitis C. As with chronic hepatitis 
B, many patients with chronic hepatitis C (CHC) cannot be cured. In CHC, IFNα 
signaling has been found to be inhibited by an upregulation of protein phosphatase 2A 
(PP2A). PP2A inhibits protein arginine methyltransferase 1 (PRMT1), the enzyme that 
catalyzes the methylation of the important IFNα signal transducer STAT1. 
Hypomethylated STAT1 is less active because it is bound by its inhibitor PIAS1. In the 
present work we investigated if similar molecular mechanisms are also responsible for 
the IFNα resistance found in many patients with chronic hepatitis B. We analyzed the 
expression of PP2A, the enzymatic activity of PRMT1 (methylation assays), the 
phosphorylation and methylation of STAT1, the association of STAT1 with PIAS1 (co-
immunoprecipitation assays), the binding of activated STAT1 to interferon stimulated 
response elements (EMSAs), and the induction of interferon target genes (real time RT-
PCR) in human hepatoma cells expressing HBV proteins, as well as in liver biopsies 
from patients with chronic hepatitis B and from controls. We found an increased 
expression of PP2A and an inhibition of IFNα signaling in cells expressing HBV proteins 
and in liver biopsies of patients with CHB. The molecular mechanisms involved are 
similar to those found in chronic hepatitis C. 
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Introduction 
More than 350 million people worldwide are chronically infected with hepatitis B virus 
(HBV) (19, 21). Chronic hepatitis B (CHB) can progress to cirrhosis and hepatocellular 
carcinoma. Approved treatments of CHB include a few nucleos(t)ide analogues such as 
lamivudine and adefovir, or interferon α (IFNα), recently in pegylated form (PegIFNα) 
(19). PegIFNα2a given for 48 weeks can induce HBeAg seroconversion in 32% of the 
patients (20). However, over 60% of patients will continue to suffer from chronic active 
hepatitis B despite PegIFNα2a therapy. The molecular mechanisms responsible for the 
ineffectiveness of IFNα treatments in CHB are not known. PegIFNα (in combination 
with ribavirin) is also the current standard therapy for chronic hepatitis C (CHC). 
Interestingly, as in CHB, PegIFNα is not effective in many patients. Over the last years, 
several molecular mechanisms responsible for viral evasion of the type I IFN system 
have been studied (10, 14). One of these mechanisms involved in the evasion of hepatitis 
C virus (HCV) has been elucidated in our laboratory over the last years:  HCV proteins 
interfere with IFNα induced signaling through the Jak-STAT pathway (3, 8, 15). 
 
The interferon system is an important component of the host response against viruses, 
and mice with deficiencies of IFN receptors or of signal transducer and activator of 
transcription 1 (STAT1) are highly susceptible to viral infections (2, 9, 23). IFN-α/β 
binding to its receptor activates members of the Jak family of tyrosine kinases, which 
then phosphorylate STAT1, STAT2 and STAT3 on a single tyrosine residue. 
Phosphorylated STATs form dimers, translocate into the nucleus, bind to promoter 
elements of interferon stimulated genes (ISGs), and activate the transcription of ISGs (4). 
This activation cycle is terminated by tyrosine dephosphorylation in the nucleus, 
followed by the decay of dimers and the nuclear export of STATs (5, 30). The pathway is 
tightly controlled by a number of inhibitory proteins (18, 27), amongst them protein 
inhibitor of activated STAT1 (PIAS1) (22). PIAS1 inhibits the last step in the Jak-STAT 
pathway, i.e., DNA binding. Complex formation between STAT1 and PIAS1 is regulated 
by an important posttranslational modification of STAT1, arginine methylation (25). 
Methylation of STAT1 is catalyzed by protein arginine methyltransferase 1 (PRMT1) and 
protects STAT1 from binding and inactivation by PIAS1 (25).  
 
We have previously reported that HCV inhibits IFN-α induced signaling at the level of 
STAT DNA binding (3, 15). Expression of HCV proteins in cells induces an increased 
expression of protein phosphatase 2Ac (PP2Ac) (8). PP2Ac was also overexpressed in 
extracts from liver cells of HCV transgenic mice and in liver biopsies from patients with 
CHC (8). PP2A is a heterotrimeric protein phosphatase consisting of a 36-kilodalton 
catalytic C subunit (PP2Ac), a 65-kilodalton structural A subunit, and a variable 
regulatory B subunit. PP2A is expressed in all cell types, is primarily a serine/threonine 
phosphatase, and is involved in a wide range of cellular processes including cell cycle 
regulation, cell morphology, development, signal transduction, translation, apoptosis and 
stress response (17, 24). PP2A regulates IFNα signaling through a strong inhibition of 
PRMT1 (6). Inhibition of PRMT1 results in a reduced level of STAT1 methylation and 
an increased binding of STAT1 by its inhibitor PIAS1 not only in cultured cells 
expressing either HCV proteins or overexpressing PP2Ac, but also in liver extracts of 
HCV transgenic mice and in liver biopsies from patients with CHC (8).  
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In the present paper, we have used a cell line that allows the controlled expression of 
hepatitis B virus, and liver biopsies from patients with CHB to analyze PP2Ac expression 
and IFNα signaling through the Jak-STAT pathway. Although HCV and HBV are 
completely unrelated viruses, we found very similar molecular mechanisms of viral 
interference with IFNα signaling. 
 
 
Materials and Methods 
Reagents, Antibodies, and Cells.  
Human IFNα (Roferon) was obtained from Hoffmann LaRoche (Basel, Switzerland). 
Purified PP2A and anti-PP2Ac were purchased from Upstate (LucernaChem, Luzern, 
Switzerland). Anti Phospho-STAT1 (Tyr 701) was purchased from Cell Signaling 
Technology (BioConcept, Allschwil, Switzerland). Anti-STAT1 was from SantaCruz 
(SantaCruz Biotechnology, Inc, Heidelberg, Germany). Monoclonal antibody to methyl 
and dimethyl arginine was purchased from Abcam (Abcam Limited, Cambridge, United 
Kingdom).14C-AdoMet (specific activity 53 mCi/mmol) was obtained from Amersham 
Biosciences (Amersham Pharmacia Biotech Europe GmbH, Dübendorf, Switzerland). C-
terminally truncated recombinant HBV core protein (amino acid sequence 1-149), used as 
immunoblot standard, was purified as previously described (1). For detection, the anti-
HBV core protein mouse monoclonal antibodies mc312 and mc158 (26) were used. 
H7TA-61 (a gift of Darius Moradpour) are Huh7 cells that constitutively express the 
tetracycline-controlled transactivator, tTA (13). H7TA-61 cells were then transfected 
with HBV expressing plasmid pTRE-HBVT, and stable clones were selected as described 
elsewhere (29). In brief, pTRE-HBVT contains a slightly overlength HBV genome 
(subtype ayw; (11)) fused behind a Tet-response element (TRE) controlled minimal 
promoter. In the absence of tetracycline or its analogue doxycycline (Dox), tTA binds to 
and activates the promoter, generating authentic HBV pregenomic RNA, the template for 
translation of the viral core and polymerase proteins, and substrate for packaging into, 
and reverse transcription inside, viral core particles. In the presence of Dox, pregenomic 
RNA transcription is suppressed to below detectability. Because the mRNAs for the 
surface proteins (L, M, and S) and X protein are transcribed from the endogenous HBV 
promoters they are not subject to Dox control, allowing for an essentially constitutive 
expression of the gene products. From one of the clones displaying tight control by Dox, 
the stable cell line Huh7.93 was established and used in this study.  
 
Patients and Biopsies. 
From August 2002, to April, 2005, all patients with chronic hepatitis B referred to the 
outpatients liver clinic of the University Hospital Basel who had a liver biopsy were 
asked for their permission to use part of the biopsy for this study. The protocol was 
approved by the ethical commission of Basel. Written informed consent was obtained 
from all patients who agreed to participate in the study. A semiquantitative grading and 
staging of all biopsies of patients with chronic hepatitis B was done according to Ishak 
(16). The expression of HBsAg and HBcAg was analyzed by routine 
immunohistochemistry methods in the Institute of Pathology of the University of Basel, 
and the expression levels were semiquantitatively determined as percentage of  
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hepatocytes with positive stainings. Control samples were from patients who underwent 
ultrasound-guided liver biopsies of focal lesions (mostly metastasis of carcinomas) and 
who were asked for their permission to obtain a biopsy from the normal liver tissue 
outside the focal lesion. Only samples with histologically confirmed absence of liver 
disease were used as controls.  
 
Preparation of Extracts from Cells and Liver Biopsies. 
Whole cell lysates and nuclear extracts were prepared as described (8). The liver biopsies 
were homogenized in 100 µl of lysis buffer (100 mM NaCl, 50 mM Tris pH 7.5, 1mM 
EDTA, 0.1 % Triton X-100, 10 mM NaF, 1 mM PMSF, and 1 mM sodium 
orthovanadate), and the lysates were then centrifuged at 14000 rpm for 5 minutes. Protein 
concentrations were determined with the BioRad Protein Assay (Bio-Rad Laboratories 
AG, Reinach, Switzerland). 
 
Immunoprecipitation and Immunoblotting.  
Immunoprecipitation and immunoblotting was done as described (8). To measure PP2Ac 
expression in human liver biopsies and in hepatoma cells, 50, 100, and 200 ng of purified 
PP2Ac was loaded on each gel. These 3 samples allowed the calculation of a standard 
curve for each gel. The intensity of each band was measured by densitometry analysis 
using NIH Image software. The amount of PP2Ac in each liver biopsie and in each 
hepatoma cell sample was then calculated according to the standard curve. 
 
Electrophoretic Mobility Shift Assay. 
EMSAs were done as described (15) using 1 µg nuclear extracts aliquots and the SIE-
m67 oligonucleotide probe . STAT1 was supershifted with antibody sc-346 from Santa 
Cruz (LabForce AG, Nunningen, Switzerland). 
 
RNA isolation, reverse transcription, and SYBR-PCR.         
Total RNA was isolated from the cells using a Perfect RNA Eukaryotic Mini kit 
(Eppendorf, Vaudaux-Eppendorf, Basel, Switzerland) according to the manufacturer's 
instructions. RNA was reverse transcribed by Moloney murine leukemia virus reverse 
transcriptase (Promega, Promega Biosciences Inc., Wallisellen, Switzerland) in the 
presence of random hexamers (Promega) and deoxynucleoside triphosphate. The reaction 
mixture was incubated for 5 min at 70°C and then for 1 h at 37°C. The reaction was 
stopped by heating at 95°C for 5 min. SYBR-PCR was performed based on SYBR green 
fluorescence (SYBR green PCR master mix, Applied Biosystems, Foster City, CA). To 
prevent genomic DNA amplification, the primers for GAP-DH and IP10 were designed 
across exon-intron junctions. The primers for GAPDH were 5` 
GCTCCTCCTGTTCGACAGTCA 3` and  5`ACCTTCCCCATGGTGTCTGA 3`. The 
primers for IP10 were 5` CGATTCTGATTTGCTGCCTTAT 3`and 5` 
GCAGGTACAGCGTACGGTTCT 3`. The ∆CT value was derived by subtracting the 
threshold cycle (CT) value for GAPDH, which served as an internal control, from the CT 
values for IP10. All reactions were run in duplicate by use of an ABI 7000 sequence 
detection system (Applied Biosystems). mRNA expression levels of IP10 was expressed 
as a fold increase according to the formula 2∆CT(PBS)-∆CT(Interferon-stimulation) . 
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Methylation Assay.  
To compare methyltransferase activity between Huh7 cells and Huh7.93 cells 20 µg of 
whole-cell lysate from each cell line were incubated in the presence of 3 µl of 14C-
AdoMet for 2 h at 37°C. The reactions were then stopped by adding 5 µl of sample 
loading buffer, and the reaction volumes were boiled for 5 min and separated on an 8% 
SDS-polyacrylamide gel. The upper part of the gel was dried and then exposed to 
Phosphorimager plate for 3 days. The lower part of the gel was cut out and stained with 
Coomassie blue to check for equal loading. 
 
 
 
Quantification of HBs antigen in the culture medium of Huh7.93 cells 
Huh7.93 cells were grown for up to 7 days in DMEM containing doxycycline. 500µl of 
the culture medium was sampled daily, and the amount of HBsAg quantified using the 
automated test system Elecsys 2010 for Hoffmann LaRoche (Basel, Switzerland) (32). As 
a negative control sample, culture medium was used. In short, Elecsys 2010 is a two-step 
sandwich assay developed and routinely used for the quantative detection of HBsAg in 
human serum or plasma.  
In the first incubation step, biotinylated and ruthenylated monoclonal antibodies directed 
against HBsAg used to detect HBsAg in the sample. Streptavidin-coated magnetic 
microparticles are then added to the mixture. In the measuring cell of the Elecsys 2010 
system, the microparticles are magnetically captured on the surface of the electrode. 
Unbound substances are removed with ProCell. Application of voltage to the electrode 
induces chemiluminescence, which is measured with a photomultiplier. 
Results are calculated with the Elecsys software by comparing the chemiluminescence 
signal obtained from the sample with the cutoff value previously obtained by HBsAg 
calibration. The amount of HBsAg in the samples is then expressed as the signal/cutoff 
ratio (s/co). 
 
Immunofluorescence with Huh7.93 and H7TA61 cells.  
Huh7.93 and H7TA61 cells were grown in a 6 well plate until 90% confluence. After 
aspirating out the culture medium, the wells were washed once with PBS. To fix the cells, 
100% methanol (-20°C) was added to the cells for 10 min at -20°C. After another 3 
washes for 5 min at RT with Tris-buffered saline tween-20 (TBST), the cells were 
incubated with blocking solution (TBST with 5% BSA) for 1h at RT. After that the cells 
were washed once with TBST, before incubation with anti-Hepatitis B virus surface 
antibody (catalog No MU364-UCE, BioGenex, San Ramon, CA, USA) overnight at 
37°C. After 3 washes with TBST, they were incubated with Cy3-conjugated secondary 
antibody (Amersham, Dübendorf, Switzerland) for 1 hour and 30 minutes at room 
temperature. Nuclear staining was performed with Hoechst (Amersham) for 5 minutes at 
room temperature. After washing, a coverslip was mounted in FluorSave Reagent 
(Calbiochem) and pictures were taken under the microscpope. 
 
 
 45 
Results 
Expression of hepatitis B virus antigens in Huh7 cells induces expression of PP2Ac.  
To investigate if HBV interferes with IFNα signaling we used the controllably HBV 
producing cell line Huh7.93 (D. Sun and M. Nassal, manuscript in preparation) and 
compared it to unmodified Huh7 cells and, selectively, to the parental tTA containing 
H7TA-61 cells. The Huh7.93 cell line is one of several lines established by stably 
transfecting the HBV expression plasmid pTRE-HBVT (see Fig. 1A, and Materials and 
Methods for details) into the Huh7 derived cell line H7TA-61 which contains the Tet-
controlled transactivator, tTA. In the absence of tetracycline or its analog doxycycline 
(Dox), tTA activates the TRE promoter, leading to transcription of HBV pregenomic 
RNA (pgRNA), and consequently core and polymerase protein translation; under these 
conditions, viral replication occurs and complete virions are generated. In the presence of 
Dox, transcription of pgRNA is suppressed such that no viral replication can be detected 
by Southern blotting (D. Sun and M. Nassal, manuscript in press, Journal of Hepatology). 
In contrast, the surface proteins, and likely the HBx protein, are constitutively expressed 
from the original endogenous viral promoters which are not Dox responsive. These data 
were corroborated here in that HBsAg was easily detected by immunostaining in the 
perinuclear cytoplasma of Huh7.93 cells (Fig. 1B) and in the supernatants of Huh7.93 
cells cultured with Dox (Fig. 1C) whereas core protein became detectable only when the 
cells were cultured in medium without Dox (Fig. 1D). 
 
 
 
FIGURE 1 
(A) Schematic map of plasmid  pTRE-HBVT used to establish the HBV expressing Huh7.93 cell line. A 
slightly overlength (1.05 x) HBV genome was cloned behind the Tet-Response-Element/minimal CMV 
promoter in plasmid pTRE2hyg (Clontech) such that transcription of the full-length pregenomic RNA of 
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HBV is controllable by the presence or absence of Dox. Without Dox, pregenomic RNA and its gene 
products core and polymerase are generated, leading to viral replication. With Dox, pregenomic RNA 
transcription is suppressed whereas the subgenomic mRNAs for the surface proteins and X protein are 
transcribed from the Dox-independent endogenous viral promoters. Arrowheads denote approximate RNA 
start sites. For authentic poly-adenylation, the genuine viral poly-adenylation signal is contained in the 3´ 
terminal redundancy of the inserted HBV genome. The position of the HBV genes are indicated by boxes. 
(B) HBs antigen is expressed in the perinuclear cytoplasm in Huh7.93 cells. 
H7TA61 (left panel) and Huh7.93 (right panel) were stained for HBsAg expression. The cell nuclei were 
stained with Hoechst dye (middle panels). The merge of the two pictures shows the cytoplasmic location of 
the HBsAg. 
 (C) Huh7.93 cells constitutively express HBsAg. Cells were grown in culture medium supplemented with 
doxycycline. The culture supernatant was sampled at the indicated time points, and HBsAg was quantified 
on an automated Elecsys 2010 system. The amount of HBsAg is expressed as signal/cutoff ratio. The cutoff 
ratio was determined with an HBsAg standard provided by the manufacturer. 
(D) De-repression of Huh7.93 cells induces expression of HBV core protein. Example of a Western blot 
showing the samples with 30 ng, 100 ng and 300 ng of recombinant truncated HBV core protein (amino 
acids 1 to 149), which appears as a monomer of 16/17 kDa and a dimer of 32-34 kDa, and lysates of 
Huh7.93 cells grown for 6 days without Dox (lane 1) or with Dox (lane 2). The asterisk indicates the 
position of the 21 kDa full-length core protein in the cells. 
 
 
Because of its role in regulating the IFN response we first measured the protein 
expression levels of PP2Ac in Huh7.93 vs. Huh7 or H7TA-61 cells, using purified PP2Ac 
for calibration (Fig. 2A). In Huh7.93 cell lysates, the mean PP2Ac expression level was 
30.2 ng/µg total protein, with a standard error of 3.5 ng/µg (Fig. 2B). This was 
significantly higher than in Huh7 cell lysates, where the mean PP2Ac expression level 
was 16.1 ng/µg total protein (standard error 2.2 ng/µg). Inducing HBV replication by 
culturing the cells without Dox did not further increase the expression level of PP2Ac 
(Fig. 2C). PP2Ac expression was also significantly increased in Huh7.93 cells when 
compared to H7TA-61 cells (Fig. 2A). Hence the increased PP2Ac level in Huh7.93 cells 
is most likely due to the expression of the HBV surface and/or X proteins. 
Because PP2Ac can inhibit the enzymatic activity of PRMT1 (6), up-regulation of PP2Ac 
expression in Huh7.93 cells should inhibit PRMT1 in these cells. We tested PRMT1 
activity in cell extracts from Huh7 and from Huh7.93-1 cells using an in vitro 
methylation assay, and found a strong inhibition of PRMT1 in Huh7.93 cells (Fig. 2D). 
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FIGURE 2 
(A) Expression of PP2Ac in human hepatoma cells expressing HBV proteins. Western blot showing PP2Ac 
standard samples with 50 ng, 100 ng and 200 ng of purified PP2Ac in lanes 1-3 (used to generate a 
calibration curve) and 3 samples each of Huh7 and Huh7.93 cell lysates, as well as 2 samples of H7TA-61 
cells (5 µg total protein in each lane).  The lower panel is a loading control showing the house keeping 
protein actin.  
(B) Graph of quantified PP2Ac expression levels in Huh7 versus Huh7.93 cells. Shown is the mean of three 
independent samples with error bars representing the standard errors of the means. The difference in the 
expression of PP2Ac between control cells and HBV proteins expressing cells is statistically significant (p 
= 0.0287, Mann-Whitney U test). 
(C) Huh7.93 cells were grown in medium with and without doxycycline as indicated. PP2Ac expression 
was measured by Western blot. No further increase of PP2Ac expression was observed in de-repressed 
cells.  
(D) PRMT1 activity is inhibited in Huh7.93 cells. 20 µg of whole-cell lysate from each cell line were 
incubated in the presence of 3 µl of 14C-AdoMet for 2 h at 37°C. The reactions were then stopped by 
adding 5 µl of sample loading buffer, and the reactionmixtures were boiled for 5 min and the proteins were 
separated on an 8% SDS-polyacrylamide gel. The upper part of the gel was dried and then exposed to 
Phosphorimager plate for 3 days. The lower part of the gel was cut out and stained with Coomassie blue to 
check for equal loading. 
 
 
IFNα signal transduction is inhibited in HBV antigen expressing cells. 
We then tested if HBV protein expression and PP2Ac overexpression inhibits IFNα 
signaling. Activated STAT1 forms dimers, translocates into the nucleus and binds to 
promoter elements of interferon stimulated genes (ISGs). We analyzed binding of 
activated STAT1 dimers by electrophoretic mobility shift assays (EMSA) with the m67-
SIE oligonucleotide probe. A strong gel shift signal was induced by IFNα in Huh7 cells 
and in H7TA-61 cells, whereas the signal was weak in Huh7.93 cells (Fig.3A). De-
repression of Huh7.93 cells by removing Dox from the culture medium did not further 
decrease the gel shift signal, indicating that the expression of the surface proteins and/or 
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the X protein is sufficient to impede IFNα signaling (Fig. 3B). This inhibition of STAT1-
DNA binding was not caused by a reduced STAT1 expression level, because STAT1 
specific bands in Western blots were equally strong in extracts from Huh7 and Huh7.93 
cells (Fig. 3C). We also observed no difference in IFNα induced phosphorylation of 
STAT1 on tyrosine 701 (Fig. 3C). Therefore, we conclude that the inhibition of STAT1 
signaling has to be downstream of STAT1 activation at the receptor kinase complex. 
 
 
FIGURE 3 
(A) IFNα induced binding of activated STAT1 is impaired in Huh7.93 cells compared to the parental cell 
lines Huh7 and H7TA-61. Electrophoretic mobility shift assay (EMSA) using the SIE-m67 oligonucleotide 
probe. Cells were left untreated (lane 1,3, 6 and 8) or they were treated for 20 minutes with 1000 U/ml 
hIFNα (lane 2, 4, 5, 7 and 9).  In lane 5, the nuclear extract of Huh7 (hIFNα treated) was incubated with 
anti-STAT1 antibody prior to the binding reaction to perform a supershift (asterisk). 
(B) Huh7.93 cells were cultured in medium with or without Dox as indicated. Cells were then stimulated 
for 20 min with 1000 U/ml hIFNα. Nuclear extracts were analysed with EMSA with SIE-m67. No further 
decrease in signal intensity was observed in de-repressed cells. 
(C) Cytoplasmatic extracts were used to perform Western blot analysis. There is no difference in the 
phosphorylation of STAT1 on tyrosine 701 between the control cells and the HBV expressing cells (upper 
part). Membrane was reblotted for STAT 1 as loading control (lower part). 
 
We next looked at the methylation status of STAT1, and found indeed a strong reduction 
in Huh7.93 cells (Fig. 4A). Since STAT1 methylation regulates the association of STAT1 
and PIAS1 (25), we did co-immunoprecipitation experiments with STAT1 and PIAS1 
antibodies. In accordance with the reduced STAT1 methylation, we detected an increased 
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binding of PIAS1 to STAT1 in Huh7.93 cells (Fig. 4B). Finally, the induction of the 
interferon stimulated gene IP10 was quantified by measuring the IP10 mRNA 
concentration after a 6 hour stimulation of cells with IFNα in Huh7 and Huh7.93 cells. 
The inhibition of the Jak-STAT pathway in Huh7.93 cells on the level of STAT1 
methylation resulted in a significantly lower induction of IP10 (Fig. 4C). 
 
 
 
FIGURE 4 
(A) STAT1 methylation (asterisk) detected by an IP-Western blot (immunoprecipitation with antibodies to 
monomethyl-dimethyl-arginine, Western blot with STAT1 antibodies) is impaired in cells expressing viral 
proteins (lane 2) compared to Huh7 (lane 1). 
(B) Binding of PIAS1 to STAT1 as detected by a co-IP (immunoprecipitation with STAT1 antibodies, 
Western blot with PIAS1 antibodies) in Huh7.93 cells is enhanced (lane 2) compared to Huh7 cells (lane 
1). Densitometric analysis of the PIAS1 signals is shown in the lower panel. The values are the integrated 
densities measured with NIH Image software and expressed as arbitrary units . 
(C) Reduced IFNα target gene induction in the presence of HBV proteins. 
Huh7 and Huh7.93 cells were stimulated with hIFNα (1000U/ml) for 6 hours. The amount of the interferon 
target gene IP10 was measured with real-time RT-PCR in three independent samples (each sample was 
measured in duplicate). The induction of IP10 mRNA was calculated as fold increase of the mRNA 
amounts in IFNα treated samples versus untreated samples. Shown are the mean values and the standard 
errors of the mean. The p-value was obtained using the ANOVA test. The transcriptional induction of IP10 
is inhibited in Huh7.93 cells (right bar) compared to the parental cell line Huh7 (left bar). 
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Upregulation of PP2Ac in chronic hepatitis B 
To corroborate the physiological relevance of the cell line derived data described above, 
we next measured the PP2Ac expression levels in liver biopsy extracts from patients with 
chronic hepatitis B and in non-infected control samples, using a semi-quantitative 
Western blot method (7). The controls were from patients who had an ultrasound-guided 
biopsy of a focal lesion in the liver. The liver parenchyma outside the lesion was biopsied 
as well, and if the histological evaluation did not show any liver pathology, the samples 
were included as controls for the present study. The median PP2Ac concentration was 
11.9 ng/µg total protein in controls, and 17.5 ng/µg total protein in biopsies from patients 
with chronic hepatitis B, a difference that was statistically significant when tested with 
the Mann-Whitney U test (p = 0.0003). Interestingly, the PP2Ac expression level 
correlated positively and significantly with the percentage of hepatocytes that stained 
positively for HBsAg (Fig. 5B, r = 0.565, p = 0.021, Fisher’s z-test). HBcAg expression 
was found in only 4 of the 18 biopsies. The PP2Ac expression level tended to be higher 
in these HBcAg positive samples, but the small sample size limits the significance of this 
result (Fig. 5C). There was no correlation between PP2Ac expression level and the 
degree of inflammation in these biopsies (data not shown).  
 
 
 
FIGURE 5: 
(A) Expression of PP2Ac in human liver biopsies of patients with chronic hepatitis B (CHB). 
PP2Ac expression levels were analysed in liver biopsies from patients with CHB and from controls using a 
semi-quantitative Western blot.  On each Western blot gel 50, 100 and 200 ng of purified PP2Ac were 
loaded to generate a calibration curve. The Western blot signal intensities of these standards and of the 
samples were measured using NIH Image Software, and the amount of PP2Ac in each sample was 
calculated according to the calibration curve. 
Box-plot diagram of quantified PP2Ac expression levels in liver biopsies of 19 patients with chronic 
hepatitis B and of 19 control patients without parenchymal liver disease. The difference in the expression of 
PP2Ac between the two groups is statistically significant (P=0.0003, Mann-Whitney U test). 
(B) Correlation between PP2Ac expression and HBsAg expression. 
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Liver biopsies from patients with CHB were stained for HBsAg expression. The percentage of hepatocytes 
with positive staining was assessed. The expression of PP2Ac correlated positively with HBsAg expression 
(r=0.565, z=0.021, Fisher’s z-test). 
(C) Correlation between PP2Ac expression and HBcAg expression. 
HBcAg expression was positive in 4 samples and negative in 14 samples. PP2Ac expression was higher in 
the group with HBcAg expression. Shown is a boxplot diagram.  
 
 
Discussion 
We have shown previously that hepatitis C virus, a member of the Flaviviridae family, 
induces the upregulation of PP2Ac in vivo (liver biopsy studies, HCV transgenic mice) 
and in vitro (tetracycline regulated HCV protein expression, HCV replicon cells) (3, 8). 
Here we report that HBV, a member of the Hepadnaviruses, also induces a significant 
up-regulation of PP2Ac. PP2A is an important serine/threonine phosphatase involved in 
many cellular processes (17, 24), and the over-expression of its catalytic subunit PP2Ac 
is likely to have important consequences for the host cell. We have concentrated on the 
effect of PP2Ac up-regulation on IFNα signaling through the Jak-STAT pathway. The 
key finding of these studies was that PP2Ac physically interacts with and inhibits 
PRMT1 in cells and also in biochemical experiments using purified proteins (6, 8). Here 
we show that Huh7 cells that express HBV antigens (Huh7.93) have elevated expression 
levels of PP2Ac compared to generic Huh7 cells as well as the tTA containing H7TA-61 
parental cells, and that the enzymatic activity of PRMT1 is strongly inhibited (Fig. 2).  
Most likely, the inhibition of PRMT1 is a consequence of PP2Ac over-expression. Like 
PP2A, PRMT1 is an important enzyme expressed in all cells and involved in arginine 
methylation of many proteins, among them histones (31) and RNA binding proteins such 
as hnRNPs, fibrillarin, nucleolin and poly(A) binding protein II (12, 28). The arginine 
methylation of STAT1 by PRMT1 modulates IFNα induced transcription of interferon 
target genes (25). Methylated STAT1 has a lower affinity to PIAS1, an inhibitor of DNA 
binding of activated STAT dimers. Because PRMT1 activity is inhibited in HBV antigen 
expressing cells, STAT1 is present mainly in its unmethylated form (Fig. 4A), and has a 
higher affinity for PIAS1 as shown in co-immunoprecipitation experiments (Fig. 4B). 
The increased binding of STAT1 by PIAS1 results in a reduced affinity of STAT1 to its 
response elements in IFNα target gene promoters, as shown by electrophoretic mobility 
shift assays (Fig. 3A). Interestingly, we did not observe any substantial differences 
between Huh7.93 cells grown in the presence vs. absence of Dox. Because the levels of 
HBV core protein and polymerase are drastically lowered by Dox, the surface proteins 
and/or the X protein are the most likely candidate antigens responsible for suppressing 
the IFN response. This question may be answered, for instance, by establishing 
comparable cell lines in which production of the individual gene products is selectively 
knocked out. Importantly, the similarly increased PP2Ac levels in liver biopsies from 
chronic hepatitis B patients vs. the non-infected controls strongly supports the 
physiological relevance of our cell line data. 
In conclusion, we propose that the molecular mechanism by which HBVsuppresses the 
IFN repsonse involves an up-regulation of PP2Ac as the primary event, with an inhibition 
of PRMT1 and a reduced STAT1 methylation as its consequence. Unmethylated STAT1 
then is bound by PIAS1 and has a reduced capacity to stimulate IFNα target genes. Our 
 52 
work identifies PP2Ac, PRMT1 and PIAS1 as potential therapeutic targets for strategies 
aimed at increasing the response rates of IFNα based treatments in chronic hepatitis B. 
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Abstract 
 
The upregulation of protein phosphatase 2 A (PP2A) is an important factor leading to an 
inhibition of IFNα signaling caused by viral protein expression. Here we describe the 
molecular mechanism responsible for PP2Ac upregulation by hepatitis C (HCV) and 
hepatitis B viruses (HBV). Both viruses induce an ER stress response leading to calcium 
release from the ER and CREB activation, most likely through calcium/calmodulin-
dependent protein kinase. CREB binds to a CRE element in the promoter of PP2Ac and 
induces its transcriptional upregulation. Since PP2Ac is involved in many important 
cellular processes including cell-cycle regulation, apoptosis, cell morphology, 
development, signal transduction and translation, its upregulation during ER stress has 
potentially important implications. Interestingly, PP2Ac upregulation was observed also 
when ER stress was induced independent from viral protein expression, and therefore 
might be an integral part of the ER stress response. 
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Introduction 
 
Hepatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis, and 
hepatocellular carcinoma worldwide (1). HCV is a parentally transmitted hepatotropic 
RNA virus. In the majority of patients HCV evades the early immune response and 
establishes a persistent infection. Type I interferons (IFNs) are important and potent 
mediators of the early host response to viral infection, and are also used for the therapy of 
chronic hepatitis C (CHC). Not surprisingly, therefore, HCV was found to interfere with 
the induction of IFNs as well as with IFN signaling in infected cells (2). The most 
important signal transduction pathway for IFNα is the Jak-STAT pathway (3). Signal 
transducers and activators of transcription (STATs) are activated at the IFN receptor by 
members of the Jak kinase family through phosphorylation of a single tyrosine residue 
(4). Phosphorylated STATs form dimers, translocate into the nucleus, and activate IFN 
target genes through binding to specific response elements in their promoters (5).  
 
We have shown previously that HCV proteins interfere with the IFNα signaling (6, 7). 
The inhibition is caused by a defective methylation of the essential transcription factor 
STAT1 (8). Because unmethylated STAT1 is bound by protein inhibitor of activated 
STAT1 (PIAS1), the binding to the promoters of a subset of interferon regulated genes 
(IRGs) is abolished, and the IFNα induced antiviral state is partially defective (9, 10). 
HCV was found to prevent STAT1 methylation through a novel pathway involving the 
inhibition of protein arginine methyltransferase 1 (PRMT1) by protein phosphatase 2A 
(PP2A) (8, 11). PP2A overexpression is the key event in this cascade, and indeed, PP2A 
was consistently found to be overexpressed in cell lines expressing HCV proteins, in liver 
extracts of HCV transgenic mice, and in liver biopsies of patients with CHC (11, 12).     
 
Recently, we found an induction of PP2A in liver biopsies from patients with chronic 
hepatitis B (CHB), and in cell lines that express hepatitis B virus (HBV) proteins (13). 
The finding was surprising because HBV and HCV are not related. We hypothesized that 
the two viruses induce PP2A overexpression through a common mechanism. Since both 
viruses use the endoplasmatic reticulum for the production of viral proteins, we 
investigated if HBV and HCV induce an endoplasmatic reticulum (ER) stress response, 
and if PP2A upregulation is induced through one or more ER stress signaling pathways.  
 
Cells monitor the physiological load placed on the ER and respond to perturbations in the 
ER function (i.e. ER stress) by a process known as the unfolded protein response (UPR) 
(14). The UPR results in the upregulation of ER-resident molecular chaperones such as 
BiP/GRP78 and GRP94 and thereby augments the folding capacity of the ER. This 
transcriptional up-regulation is mediated through the activation of the ER resident type I 
transmembrane kinase and endonucleases IRE1α and IRE1β that differentially splice the 
mRNA of Xbp-1, an important transcription factor for the activation of UPR target genes 
(15-18). The UPR also involves the activation of the ER resident type I transmembrane 
protein kinase PERK and the transcription factor ATF6  (19-21). The cytoplasmic kinase 
domain of PERK phosphorylates the α subunit of eukaryotic translation initiation factor 2 
(eIF2-α). Phosphorylated eIF2-α inhibits the association of mRNA with the ribosomal 
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60S and 40S subunits and thereby inhibits the translation of proteins. Finally, the UPR 
also activates the proteasome dependent degradation of proteins through a process called 
ER-associated degradation (ERAD) (22). All these systems work in a coordinated fashion 
to improve the efficiency of folding, processing and export of secretory proteins, to 
reduce the flow of newly translated proteins in the ER, and to remove the fraction of 
polypeptides that fail to fold correctly. 
 
It is well known that viral infection of a cell can induce ER stress. For HCV it has been 
published that the expression of envelope E1 and E2 proteins (23, 24), the expression of 
HCV core proteins (25) or the transfection of subgenomic replicons (26) induce an ER 
stress response. But there are also publications reporting that HCV disrupts (part of) the 
ER stress response (27, 28). 
 
In the present work we report that HCV and HBV protein expression in cells induces an 
activation of ER stress response pathways. Furthermore, pharmacological induction of 
ER stress with thapsigargin or tunicamycin induced an upregulation and overexpression 
PP2A. This PP2A induction was dependent on calcium and cyclic AMP response element 
binding protein (CREB). We propose that the upregulation of PP2A observed in HBV 
and HCV infections is a consequence of ER stress induced by these viruses. 
 
 
 
Materials and Methods 
 
Reagents, Antibodies, and Cells 
To induce ER-stress, cells were treated with 1 µM thapsigargin or 1.5µg/ml tunicamycin. 
To decrease cytosolic calcium levels, cells were treated with 3 µM BAPTA-AM. All 
these compounds were obtained from Sigma (Sigma-Aldrich Chemie, Buchs, 
Switzerland). Anti phospho-CREB, anti-CREB, anti-phospho-eIF2alpha, anti-eIF2alpha, 
and anti-BiP were purchased from Cell signaling technology (BioConcept, Allschwil, 
Switzerland). Anti-PP2Ac was purchased from Upstate (LucernaChem, Luzern, 
Switzerland). 
U-2 OS human osteosarcoma-derived, tetracycline (tet)-regulated cell lines UHCV-57.3, 
which inducibly express the entire HCV polyprotein derived from an HCV H consensus 
cDNA (29), and the parental cell line UTA6 transfected only with the tetracycline 
transactivator (tTA), and UGFP-20 cells which inducibly express green fluorescent 
protein, were a gift from Darius Moradpour and have been described previously (30). 
Human hepatoma cells Huh7 were grown in Dulbecco`s minimal essential medium 
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin. H7TA-61 (a gift 
of Darius Moradpour) are Huh7 cells that constitutively express the tetracycline-
controlled transactivator, tTA (31). Huh7.93 cells (a gift from Michael Nassal) are 
derived from H7TA-61 after transfection with the HBV expressing plasmid pTRE-
HBVT.  
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Preparation of cell extracts and immunoblotting 
Whole cell and nuclear extracts were prepared as described (8). Protein concentration 
was determined with the BioRad Protein Assay (Bio-Rad Laboratories AG, Reinach, 
Switzerland). Immunoblotting was performed as described (8). 
 
RNA isolation, reverse transcription, and XBP-1 PCR 
Total RNA was isolated from cells using a Perfect RNA Eukaryotic Mini Kit (Eppendorf, 
Vaudaux-Eppendorf, Basel, Switzerland) according to the manufacturer`s instructions. 
RNA was reverse transcribed by Moloney murine leukemia virus reverse transcriptase 
(Promega, Promega Biosciences Inc., Wallisellen, Switzerlend) in the presence of 
random hexamers (Promega) and deoxynucleoside triphosphate. The reaction mixture 
was incubated for 5 min at 70°C and then for 1 h at 37°C. The reaction was stopped by 
heating at 95°C for 5 min. To amplify XBP1 mRNA, a PCR reaction with the cDNA was 
performed for 30 cycles (94° for 30 s; 58°C for 30 s and 72°C for 1 min (but 5 min in a 
last cycle step)) using 5`-CTGGAACAGCAAGTGGTAGA-3`and 5`-
CTGGGTCCTTCTGGGTAGAC-3` (32). 398bp and 424bp fragments representing 
spliced and unspliced XBP1, respectively, were  analyzed on a 2%  agarose gel. 
 
Real time RT-PCR for PP2Ac 
The cDNA was used to perform SYBR-PCR based on SYBR-Green Fluorescence 
(SYBR-Green PCR Master Mix, Applied Biosystems, Foster City, CA). To prevent 
influence from genomic DNA amplification, the primers were designed across exon-
intron junctions. The primers for GAPDH were 5-GCTCCTCCTGTTCGACAGTCA-3 
and 5-ACCTTCCCCATGGTGTCTGA-3 and the primers for PP2Ac were 5' 
CCACAGCAAGTCACACATTGG 3' and 5' CAGAGCACTTGATCGCCTACAA 3'. 
The CT value was derived by subtracting the threshold cycle (CT) value for GAPDH, 
which served as an internal control, from the CT values for PP2Ac, respectively. All 
reactions were run in duplicate using the ABI 7000 Sequence Detection System (Applied 
Biosystems). mRNA expression level of PP2Ac was expressed as a fold increase  
according to the formula 2 ∆CT(PBS)-∆CT(HCV expression). 
 
Electrophoretic Mobility Shift Assay (EMSA) 
2 µg of nuclear extract aliquots were used to perform EMSAs. Oligonucleotides were 
annealed to double-strand oligonucleotides and then labeled with (γ−32P) CTP using 
Klenow polymerase. The sequence of the used CRE-oligo was 5`-
GACGCCGGCCTGACGTCACCACGCC-3’ (33). The CREB complex was supershifted 
with antibody 86B10 from Cell Signaling Technology (BioConcept, Allschwil, 
Switzerland). 
 
CREB siRNA treatment of UHCV 57.3 cells expressing HCV proteins 
UHCV 57.3 cells were transfected using Lipofectamine 2000 from Invitrogen (Basel, 
Switzerland) according to the manufacturer`s instructions with 20 µl of a 20 µM solution 
of CREB small interfering RNA (siRNA) duplexes from QIAGEN (Basel, Switzerland) 
or with a corresponding amount of nonsilencing siRNA duplex from QIAGEN. Four 
hours after transfection, cells were recovered for 48 h in Dulbecco`s minimal essential 
medium supplemented with 10% fetal calf serum, antibiotics for selection and 
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tetracycline to inhibit expression of viral proteins. After 48 h, tetracycline was removed 
from the medium and cells were grown for additional 24h to induce the expression of 
viral proteins.  Whole cell extracts were prepared to perform Western blot analysis. 
 
Calcium release of the endoplasmatic reticulum 
Changes in calcium concentrations of UHCV 57.3 cells were monitored using the 
fluorescent calcium indicator fura-2/AM (Sigma, St. Louis, MO) at a final concentration 
5 µM as described (34-36). Cells were loaded with fura-2 for 30min at 37°C, and then 
washed once by centrifugation, counted and the same number of cells was resuspended in 
Ca2+-free Krebs-Ringer medium containing 0.5 mM EGTA and placed in a cuvette 
thermostated at 37°C. Fluorescence changes (ratio 340/380 nm) were measured in a 
Perkin-Elmer LS50 spectrofluorimeter equipped with a magnetic stirrer. All 
measurements were made in Ca2+-free Krebs-Ringer buffer containing 0.5 mM EGTA. 
Experiments were performed at least four times on four different days. 1 µM thapsigargin 
(Sigma) was added to empty the endoplasmatic reticulum. 
 
 
Results 
 
Inducible expression of HCV proteins activates multiple endoplasmatic reticulum 
stress pathways 
We first tested if the expression of viral proteins in cells induces an ER stress response. 
UHCV57.3 cells contain the entire open reading frame of a HCV consensus cDNA (30). 
The transcription of the HCV cDNA is under the control of a tetracycline regulated 
transactivator (tTA). HCV protein expression is repressed when UHCV57.3 cells are 
cultured in tetracycline containing medium. In the absence of tetracycline, UHCV57.3 
cells express all HCV proteins (30). As shown in Figure 1, the expression of HCV 
proteins in UHCV57.3 cells induced the upregulation of the ER chaperon BiP and the 
splicing of XBP-1 mRNA, demonstrating the activation of an ER stress response in these 
cells. Consistent with our previous data, HCV protein expression also induced the 
expression of PP2Ac. ER stress and PP2Ac induction were specific for HCV protein 
expression, because neither was found in the control cells UTA6 and UGFP. UTA6 cells 
are the parental cells of UHCV57.3 cells: they stably express tTA but have no HCV 
cDNA. UGFP cells were derived from UTA6 cells by stable transfection of a plasmid 
encoding green fluorescent protein (GFP). When cultured without tetracycline, UGFP 
cells express high amounts of GFP (30). Interestingly, the expression of HBV proteins in 
Huh7.93 cells also activated an ER stress response (Figure 1E). Again, the control cell 
line H7TA61 (the parental cell line of Huh7.93 that contains only tTA but no HBV 
cDNA) did not show an induction of BiP. 
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Figure 1: Expression of viral proteins leads to the induction of ER-stress markers and to an upregulation of 
PP2Ac. (A) UHCV57.3 cells express all hepatitis C virus (HCV) proteins when cultured in medium without 
tetracycline (HCV core protein expression is shown as an example). Control cells for HCV protein 
expression were UTA6 cells (contain the tetracycline transactivator tTA, but no viral transgene) and UGFP 
(inducible express the green fluorescent protein when cultured without tetracycline). (B) Expression of 
HCV proteins in UHCV57.3 cells upregulates PP2Ac. The upper panel shows an example of a Western blot 
with UHCV57.3, UTA and UGFP cells cultured in medium with or without tetracycline as indicated. The 
lower panel shows a statistical evaluation of densitometric measurements (arbitrary units) of the PP2Ac 
bands from multiple independent experiments (Number of experiments indicated below graphs). (C) 
Expression of HCV proteins in UHCV57.3 cells induces the ER-chaperone BiP. The upper panel shows an 
example of a Western blot. The lower panel shows a statistical evaluation of densitometric measurements 
(arbitrary units) of the BiP bands from multiple independent experiments (Number of experiments 
indicated below graphs). For all Western blot, 10µg total protein were loaded and separated on a 12% SDS-
PAGE. (D) The activation of the IRE1-Xbp1 pathway is shown by means of XBP1 mRNA splicing 
(unspliced XBP1 mRNA is the upper band, and the spliced form of XBP1 is the lower band, indicated with 
an asterisk). No ER stress activation is observed in UTA6 and UGFP control cells. (E) Expression of 
hepatitis B virus proteins in Huh7.93 cells also induces ER stress as exemplified by the induction of BiP 
(example of a Western blot is shown in the upper panel). The lower panel shows a statistical evaluation of 
densitometric measurements (arbitrary units) of the BiP bands from multiple independent experiments 
(Number of experiments indicated below graphs). The control H7TA61 cells contain the tTA, but no viral 
cDNA.  
 
 
 
Pharmacological induction of ER stress induces PP2Ac expression 
Next we tested if pharmacological induction of ER stress could induce PP2Ac expression 
independent from viral protein expression. Treatment of untransfected Huh7 cells for 8 
hours with thapsigargin, an inhibitor of the endoplasmatic reticulum Ca2+ ATPase, 
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induced a classical ER stress response, documented by an upregulation of BiP, a 
phosphorylation of P-eIF2α and splicing of the XBP1 mRNA (Figure 2A). Interestingly, 
PP2Ac was also strongly upregulated both at the protein (Figure 2A) and mRNA level 
(Figure 2B). The same upregulation of PP2Ac was observed after treatment of Huh7 cells 
with tunicamycin, another widely used inducer of ER stress that inhibits N-linked 
glycosylation of proteins in the ER and leads to the accumulation of unfolded protein 
(Figure 2C). To prove that pharmacological induction of ER stress could induce PP2Ac 
expression independent of HCV protein expression, UHCV57.3 cells were cultured in 
tetracycline supplemented medium to repress the expression of viral proteins, and then 
treated with thapsigargin for 8 hours. The treatment activated the ER stress response 
pathways (BiP, XBP1 mRNA splicing), and caused a strong induction of PP2Ac (Figure 
2D). The same PP2Ac induction was observed in the parental cell line UTA6. We 
conclude that the upregulation of PP2Ac in the human hepatoma cell line Huh7 and the 
human osteosarcoma derived cell lines UHCV57.3 and UTA6 is an integral part of the 
ER stress response in these cells.   
 
 
 
 
Figure 2: Pharmacological induction of ER-stress leads to an upregulation of PP2Ac that is independent 
from viral protein expression. 
(A) Western blots showing the expression of BiP, PP2Ac, P-eIF2alpha and eIF2alpha and RT-PCR 
showing the spliced and the unspliced form of XBP1 in Huh7 cells after treatment with 1 µM of the ER-
stress inducer thapsigargin for 8h. For PP2Ac induction, a statistical evaluation of densitometric 
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measurements (arbitrary units) of the PP2Ac bands from multiple independent experiments is shown below 
the Western blot example (Number of experiments indicated below graphs). 
(B) PP2Ac mRNA concentrations in cells were measured by real-time RT-PCR. Treatment of Huh7 cells 
for 8h with thapsigargin resulted in a more than two-fold increase of the PP2Ac mRNA. 
(C) Western blot showing the expression of PP2Ac and BiP in Huh7 cells after treatment with 1.5 µg/ml 
tunicamycin for 8h. 
(D): Western blot showing the induction of ER-stress markers (BiP and XBP-1 splicing) and the 
upregulation of PP2Ac after treatment of tetracycline repressed UHCV 57.3 (left panel) and UTA-6 cells 
(right panel) with 1 µM thapsigargin for 8h. For all Western blot shown in figure 2, 10µg total protein were 
loaded per lane and separated on a 12% SDS-PAGE. 
 
 
PP2Ac upregulation is mediated by CREB 
The transcriptional upregulation of stress response genes is mediated through the cis-
acting promoter elements ER stress response element-I (ERSE-I) and ERSE-II (37-39). 
We therefore scanned the promoter of PP2Ac for the presence of these sites, but did not 
find homologous sequences. However, a canonical CREB binding site  (TCACGTCA) is 
present at position –241 to –233 of the PP2Ac promoter (40). Indeed, CREB was 
phosphorylated (activated) in UHCV57.3 cells that were induced to express viral proteins 
and thereby had an activated ER stress response (Figure 3A). The activation of CREB by 
HCV protein expression was confirmed with an electrophoretic mobility shift assay 
(EMSA) using a CRE oligonucleotide (Figure 3B). CREB was necessary for PP2Ac 
upregulation, because pretreatment of cells with a CREB specific siRNA prevented the 
HCV protein induced PP2Ac over-expression (Figure 3C).  
 
 
 
 
Figure 3: HCV protein expression leads to the activation of the transcription factor CREB. 
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(A) The phosphorylation of CREB was analyzed by Western blot of whole cells extracts of UHCV57.3 
cells grown in the presence or in the absence of tetracycline (upper panel).  Below is the loading control, 
showing the amount of CREB in both samples. 
(B) Electrophoretic mobility shift assay (EMSA) with a CRE oligonucleotide and nuclear extracts of 
UHCV57.3 cells that have been grown in the presence of tetracycline (lane 1) or without tetracycline (lanes 
2-5). The de-repression of HCV protein expression in UHCV57.3 cells induced a CREB shift (lanes 2-4) 
that could be supershifted (*) with a CREB specific antibody (lane5). 
 (C) Silencing of CREB prevents the overexpression of PP2Ac in UHCV57.3 cells with induced HCV 
protein expression. UHCV 57.3 cells were transfected with siRNA against CREB (lane 3) or with non-
silencing siRNA (lane 4) for 48h. Cells were then cultured for an additional 24h in the absence of 
tetracycline to induce HCV protein expression and ER stress. Compared to cells grown in tetracycline 
containing medium (lane 1), UHCV57.3 cells cultured without tetracycline showed the expected up-
regulation of PP2Ac (lane 2). This upregulation was prevented by pretreatment of cells with a CREB 
specific siRNA (lane 3), but not by a non-sense siRNA (lane 4). The lower panel shows the expression 
level of CREB in the different samples. 
 
 
 
ER stress induced calcium release from the endoplasmatic reticulum activates 
CREB 
CREB is an ubiquitously expressed transcription factor that can be activated by G protein 
coupled receptors via cyclic AMP (cAMP) and protein kinase A. Alternatively, CREB 
can also be phosphorylated on the same serine residue (Ser133) by members of the Ca2+-
calmodulin-dependent protein kinase (CaM kinase) family (41). Calcium is involved in 
the induction of ER stress responses (42, 43), and we therefore tested if CREB 
phosphorylation in response to HCV protein expression is caused by Ca2+. Indeed, Huh7 
cells that were treated with CaCl2 showed the same amount of phosphorylated CREB as 
Huh7 samples treated with thapsigargin (Figure 4A). In accordance with a direct role of 
CREB in the upregulation of PP2Ac, CaCl2 treatment of Huh7 cells also induced an over-
expression of PP2Ac (Figure 4B). To test if the expression of HCV proteins caused a 
release of Ca2+ from the ER, we indirectly measured the Ca2+ content in the ER in 
UHCV57.3 cells. To this end, cells were loaded with the fluorescent calcium indicator 
fura-2/AM and indirect measurement of the Ca2+ content in the ER were obtained by 
treating the cells with thapsigargin, an inhibitor of endoplasmatic reticulum Ca2+ ATPase. 
The peak Ca2+ release induced by this treatment is an indicator of the amount of Ca2+ 
present in the ER. As shown in figure 4C, HCV protein expression in UHCV57.3 cells 
significantly reduced the Ca2+ content in the ER. Thus the expression of HCV proteins 
induces an ER stress response leading to a decrease of the size of the intracellular Ca2+ 
stores, via a release of Ca2+ from the ER. This in turn stimulates CaM kinase, leading to 
the phosphorylation of CREB. In support of this hypothesis, when the increase of Ca2+ in 
the cytoplasma was prevented by the calcium chelator BAPTA, HCV protein expression 
no longer caused an upregulation of PP2Ac (Figure 4D).   
 
 
 65 
 
Figure 4: CREB activation and PP2Ac upregulation is mediated through Ca2+ signaling. 
(A) Western blot analysis with phospho-CREB specific antibodies. Huh7 cells were treated for 16h with 
1mM CaCl2 or 1 µM thapsigargin. 20µg total protein were loaded per lane and separated on a 12% SDS-
PAGE. 
(B) Huh7 cells were treated with PBS or with 1 mM CaCl2 for 16h as indicated and whole cells extracts 
were analyzed for the expression of PP2Ac by Western blot (upper panel shows an example of a Western 
blot). The lower panel shows a statistical evaluation of densitometric measurements (arbitrary units) of the 
PP2Ac bands from multiple independent experiments (Number of experiments indicated below graphs). 
(C) Peak calcium released from the ER by thapsigargin was measured after loading the cells with the 
fluorescent calcium indicator fura-2/AM. The peak calcium induced by addig 1µM thapsigargin was 
significantly lower in cells that were grown in the absence of tetracycline to induce HCV protein 
expression. Results are expressed as means (+/- SE) of 16 experiments. Measurements were performed on 
1.5 x 106 cells. Statistical analysis was done with Anova. 
(D) UHCV 57.3 cells were grown in the presence of Tet (lane 1) or in the absence of Tet for 24h (lane 2 
and 3) to induce expression of HCV proteins. One of the HCV protein expressing samples was treated with 
3 µM BAPTA-AM to prevent an increase in cytosolic free Ca2+ (lane3). Whole cell extracts were done and 
PP2Ac levels were analyzed by Western blot. The lower panel shows a densitometric analysis of the 
Western blot signals (arbitrary units). 
 
 
 
Discussion 
 
PP2A is involved in a wide range of cellular processes including cell cycle regulation, 
cell morphology, development, signal transduction, translation, apoptosis and stress 
response (44). PP2A is a heterotrimeric serine/threonine phosphatase consisting of a 36 
kDa catalytic C subunit (PP2Ac), a 65 kDa structural A subunit and a variable regulatory 
B subunit. It is a very abundant protein that accounts for an estimated 0.3% to 1.0% of 
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the total cellular proteins (45). Given its many functions and interactions with other 
cellular proteins, it is not surprising that the expression of PP2A is tightly regulated (44, 
46, 47). However, downregulation of PP2Ac has been found, for instance during all-
trans-retinoic acid-induced differentiation of HL-60 cells (48) or during peroxisome 
proliferator-activated receptor-γ induced adipocyte differentiation (49). Likewise, 
upregulation of PP2Ac was found in macrophages in response to colony-stimulating 
factor 1 (50), and we have previously reported that HCV protein expression in cells or in 
livers of transgenic mice induced the overexpression of PP2Ac (8). Here we report for the 
first time that PP2Ac is upregulated during ER stress, no matter if induced 
pharmacologically with thapsigargin or tunicamycin, or through the expression of viral 
proteins. 
  
There are several potential implications of PP2A upregulation for the ER stress response. 
For example, ER stress is known to inhibit the cell cycle in G1 through the activation of 
PERK (51). Interestingly, PP2A has been shown to keep the M-phase-promoting factor 
(MPF, a complex consisting of the p34cdc2 kinase (Cdc2 or Cdk1) and cyclin B) in its 
inactive form, preventing the G2/M transition (52, 53). The upregulation of PP2A during 
ER stress might contribute to cell cycle exit by inhibiting the G2/M transition. 
  
Chronic ER stress results in programmed cell death through the activation of proapoptotic 
pathways that involve IRE1, TRAF2, caspase12, caspase3, CHOP and BCL-2 family 
members (19).  CHOP, a proapoptotic transcription factor induced through ATF4 and 
ATF6 (54), suppresses the transcription of anti-apoptotic bcl-2 (55), thereby promoting 
cell death. PP2A has the opposite effect of enhancing the resistance to apoptosis in 
stressed cells. By dephosphorylating bcl-2 on serine-87, PP2A protects blc-2 from 
proteasome-dependent degradation (56) and enhances its anti-apoptotic function (57). 
The upregulation of PP2A by ER stress might therefore restrain the effects of the 
proapoptotic signals generated through CHOP. 
 
The PP2Acα promoter contains neither an ERSE-I nor an ERSE-II binding site for the 
classical ER stress transcription factors XBP1 and ATF6. The promoter also lacks TATA 
and CCAAT boxes. Instead it has several Sp1 binding sites and a cAMP-regulatory 
element (CRE) (40). We therefore investigated if HCV protein expression leads to CREB 
activation, using an antibody that is specific for the Ser133 phosphorylated form of 
CREB (with some crossreactivity for ATF1), and found a strong induction of CREB 
phosphorylation and CREB DNA binding. CREB activation was required for PP2Ac 
induction, because CREB specific siRNA knockdown prevented PP2Ac upregulation by 
HCV proteins. Interestingly, PP2Ac is involved in the negative regulation of CREB. 
PP2A dephosphorylates Ser133 of CREB (58) and PP2A inhibits calcium/calmodulin-
dependent protein kinase (CaMK) thereby preventing CREB phosphorylation (59). The 
HCV protein induced upregulation of PP2Ac through Ca2+ and CREB could therefore 
constitute a negative feedback loop that limits the extent of CREB mediated 
transcriptional regulation. 
 
The presented findings also have implications for human chronic viral hepatitis. First, 
PP2Ac upregulation is not only observed cell culture systems and transgenic mice (8), but 
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also in liver biopsy samples from patients with chronic hepatitis C (12). Importantly, 
PP2Ac overexpression per se (in cells without HCV protein expression) inhibits IFNα 
induced intracellular signaling (8), providing an obvious advantage for viral replication 
and persistence. Viral interference with IFNα signaling has been described for a growing 
number of viruses, and in many cases a specific function of an individual viral protein 
that was responsible for the interference with IFNα signaling could be identified (60, 61). 
In the past, we have analyzed a panel of cell lines that express individual HCV protein 
with the aim of identify ingthe viral protein(s) responsible for the inhibition of IFNα 
signaling and the upregulation of PP2Ac. However, we could not unequivocally identify 
the responsible protein. We then discovered that the infection with hepatitis B virus also 
lead to an upregulation of PP2Ac in the liver. The present work provides now a unifying 
hypothesis how these completely unrelated viruses induce a similar cellular response that 
finally leads to an inhibition of IFNα signaling. Both viruses activate an ER stress 
response, and through the Ca2+ dependent activation of CREB transcriptionally 
upregulate PP2Ac, a key enzyme for many cellular processes. The negative regulation of 
IFNα signaling through PP2A is an obvious advantage for the viruses, but the role of 
PP2A in regulating the cell cycle and apoptotic signaling pathways might be as 
important.  
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4. Discussion 
 
4.1 Inhibition of the IFN Signaling by HCV  
 
The resistance of HCV to IFNα treatment is a major health problem worldwide, and the 
mechanisms responsible for the treatment failure in up to 50% of treated patients are still 
not completely understood. A lot of effort has been made during the last years to 
investigate the interactions of the hepatitis C virus with the host immune system and to 
identify new targets for the development of a vaccine or an improved therapy. It was 
shown that the E2 protein of HCV interferes with the double-stranded RNA-activated 
protein kinase (PKR). PKR is induced by IFN and inhibits protein synthesis by 
phosphorylation of the translation initiation factor eIF2. HCV E2 from most HCV isolates 
contains a 12-amino acid sequence that is similar to the PKR autophosphorylation site 
and the eIF2 phosphorylation site, a target of PKR. Because of this sequence homology 
of E2 to PKR and eIF2 phosphorylation site, it was suggested that the E2 protein  binds to 
and inhibits PKR in vitro and does so in mammalian cells and yeast (113). Another HCV 
protein that interacts with PKR is the nonstructural protein NS5A. NS5A repressed PKR 
activity through a direct interaction with the protein kinase catalytic domain. A specific 
amino acid sequence, the socalled interferon sensitivity-determining region (ISDR) of the 
HCV NS5A was required for this interaction (114). A third mechanism of inhibiting PKR 
by HCV involves the viral internal ribosome entry site (IRES). A region of the viral RNA 
comprising part of the IRES was able to bind to PKR in competition to double-stranded 
RNA and to prevent autophosphorylation and activation of the kinase in vitro. However 
the HCV IRES itself had no PKR-activating ability (115). 
The induction of interleukin 8 (Il-8) by nonstructural protein NS5A displayed an 
additional mechanism to inhibit the antiviral actions of IFN. IL-8 is a 71-amino-acid 
chemotactic cytokine that is induced primarily by the cytokines IL-1 and tumor necrosis 
factor alpha (TNF-) and that is produced by many cells, including fibroblasts and 
hepatocytes. IL-8 is a principal mediator of the inflammatory response to many viruses 
and bacteria and it inhibits the antiviral actions of IFN in vitro (116). 
Other important components of the innate immune system are the interferon regulatory 
factors (IRFs), transcription factors that initiate a cellular antiviral state (117). IRF-3 is a 
latent cytoplasmic factor that is activated through phosphorylation. Phosphorylated IRF-3 
translocates to the nucleus, where it induces transcription of type I IFNs and other 
antiviral genes (118). HCV RNA replication activates IRF-3 and stimulates cellular 
antiviral responses  (119). Further studies identified RIG1, a sensor-protein for double 
strand RNA, as the sensor of HCV RNA and inducer of IFNβ (120). The adaptor protein 
that coupled RIG1 to the downstream kinases (IKKε, TKB1) that phosphorylate IRF was 
CARDIF (also known as MAVS, VISA and IPS-1) (121). HCV NS3/4 protease cleaved 
and inactivated CARDIF and thereby blocked the induction of IFNβ (121)).  
Furthermore, HCV counteracts the antiviral activity of IFN by inhibiting the Jak-STAT 
pathway. The work presented in this thesis contributed substantially to the current 
understanding of the mechanisms of HCV interference with IFNα signaling. The 
hallmark of this inhibition is the hypomethylation of STAT1. Reduced methylation of 
STAT1 was found in livers of mice expressing the whole HCV open reading frame, in 
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liver biopsies of CHC patients and in osteosarcoma cells expressing HCV proteins. 
Hypomethylated STAT1 showed an increased association with PIAS1. The association of 
PIAS1 to STAT1 prevented the binding of STAT1 to promoters of IFNα target genes 
upon IFNα stimulation and therefore leaded to a reduced induction of IFNα responsive 
genes. Beside the hypomethylation of STAT1, an increased level of PP2Ac was 
observed, that leaded to the hypothesis that PP2Ac inhibits the enzymatic activity of 
PRMT1 (30, Blindenbacher, 2003 #164). We provide the following strong evidence that 
this is indeed the case: first we could show elevated PP2A level in cells expressing HCV 
proteins, in HCV subreplicon cells and in liver biopsy samples of CHC patients. 
Interestingly, in biopsy samples of genotype 1 infected patients, the level of PP2A was 
higher than in samples of patients infected with genotype 3. This result is in accordance 
with the finding that genotype 1 infected patients are more difficult to treat and have a 
higher risk to develop chronic infection than patients with other genotypes. Second, we 
show that the increase expression of PP2Ac directly inhibits the enzymatic activity of 
PRMT1 leading to STAT1 hypomethylation. Consequently, PIAS1 associates to STAT1 
and blocks the binding of activated STAT1 to the promoter of target genes. Third, the 
inhibitory effect of PP2Ac on PRMT1 releases NS3 helicase from arginine methylation, 
resulting in an increase replication of the virus. 
 
 
 
 
4.2 Antiviral therapy for chronic hepatitis C 
 
In 1989, the hepatitis C virus was discovered in the United States as causative agent of 
posttransfusion non-A, non-B hepatitis (Science 1989 Choo). It is estimated that 170 
million people worldwide are infected with HCV (WHO). Many cases are asymptomatic 
and result in hepatic disease, manifested as hepatic cirrhosis or cancer. IFN therapy for 
hepatitis C dates from 1986, when Hoofnagle et al (1986, N Engl J Med) reported the 
normalization of serum alanine aminotransferase (ALT) levels following administration 
of recombinant human IFNα to patients with non-A, non-B hepatitis. IFN was shown to 
be biochemically effective as an antiinflammatory drug before the discovery of HCV in 
1989 (31). The therapeutic outcome to IFN can be classified as sustained virologic 
response (SVR), relapse, or nonresponse. SVR means complete elimination of HCV, 
defined as the loss of detectable HCV RNA during therapy and for at least 6 months after 
therapy. Relapse is defined as being HCV-negative at the end of treatment but HCV-
positive within 6 months after therapy. Finally nonresponse is defined as the absence of 
an HCV-negative period during the treatment. Unfortunately, therapy with IFNα alone 
had only limited success with a sustained response rate of approx. 20%. A major advance 
came with the addition of the broad-spectrum antiviral agent ribavirin to IFNα therapy, 
which more than doubled the sustained response rate to 35-40% (122). Further 
improvement has been achieved by the development of pegylated interferon, in which a 
large molecule of poly (ethylene glycol) (PEG) is covalently attached to recombinant 
IFNα, resulting in an active molecule with a longer half-life, better pharmacokinetic 
profile and better rate of virological response (123). The combination of PEG-IFNα with 
ribavirin yields sustained response rates up to 56%.  Viral factors that correlate with a 
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sustained response to combination therapy are genotype, viral load and quasispecies 
diversity. But host factors also affect the chance of clearance of the virus, albeit less so 
than the genotype does. These include age, race, gender, obesity and degree of hepatic 
fibrosis. Among these factors, racial differences in response rates are the most striking 
(124). The reasons for the racial differences in response rates to pegylated interferon and 
ribavirin therapy for hepatitis C are not known. The current commercially available forms 
of IFNα used for for hepatitis C are α2a, α2b and consensus IFN. IFNα has potent 
antiviral activity but does not act directly on the virus or replication complex. Rather, it 
acts by inducing IFN-stimulated genes (ISG), which establish a non-virus-specific 
antiviral state within the cell (125). Microarray analysis show that hundreds of genes are 
induced by type-1 IFN via the Jak-STAT signaling pathway, many of these genes related 
to antiviral activity but others involved in lipid metabolism, apoptosis, protein 
degradation and inflammatory cell responses (126). 
Because of the low efficiency and the adverse side effects of IFNα-ribavirin combination 
therapy, new treatment regimens are needed. Major research efforts have concentrated on 
the identification of agents that inhibit specific steps in the life cycle of the virus. A 
straightforward approach was the development of antiviral drugs that blocks essential 
viral enzymes. Although all HCV enzymes are good targets for therapeutic intervention, 
the NS3-4A serine protease and the NS5B RNA polymerase have emerged as the most 
popular targets. A number of competitive inhibitors of NS3 protease as well as nucleoside 
and non-nucleoside inhibitors of the NS5B polymerase have been developed. Some of 
theses compounds are already used in early-phase clinical trials. But the problem of these 
compounds is the development of drug-resistant viruses under the selective pressures 
exerted by antiviral drugs. The fast turnover rate and the intrinsic low fidelity of the HCV 
replication machinery endows the virus with the ability to fully explore its genome space 
and quickly come up with mutations that render it resistant to antiviral drugs. Another 
interesting approach to develop new drugs against HCV is the use of RNA interference 
(siRNA). In tissue culture, siRNA, as well as vector-encoded short hairpin RNA 
(shRNA) directed against the viral genome, effectively blocks the replication of HCV 
replicons, the most effective siRNA are capable of completely eradicating HCV from 
more than 98% of the replicon bearing cells (127). Despite the positive outcome of the in 
vitro studies, there is the problem of efficient in vivo delivery of siRNA. Chemically 
modified siRNA seem able to inhibit HCV replication in tissue culture and also in a 
mouse model of HCV infection (Han, Symposium Heidelberg 2004). 
A completely other approach is the development and use of immunomodulatory agents. 
The experience with the IFN therapy has demonstrated, that HCV infection can be 
eradicated by agents that stimulate the host immune system. Following this line, synthetic 
agonists of Toll-like receptors (TLRs) 7 and 9 have progressed through early-phase 
clinical trials. TLR are molecules that sense the presence of invading microorganisms and 
initiate acute inflammatory responses by induction of antimicrobial genes and pro-
inflammatory cytokines and chemokines. For example potent agonosts of TLR-9 are 
short synthetic oligonucleotides containing one or more unmethylated CpG motifs 
flanked by specific sequences. 
In the present work, we show another approach to improve the IFNα therapy by 
overcoming the inhibition of the Jak-STAT signaling through the hepatitis C virus. As 
described above, the inhibition of the signaling is caused by the decreased activity of 
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PRMT1 that cause an accumulation of hypomethylated STAT1, and as a consequence 
increased association of STAT1 with PIAS1 and therefore less IFNα target gene 
induction. For the methylation of STAT1, PRMT1 uses S-adenosylmethionine (AdoMet, 
SAMe) as a methylgroup donor. The products of this reaction are methylated STAT1 and 
S-adenosylhomocysteine that is converted via homocysteine into methionine. As last step 
of this biochemical cycle, methionine is transformed into AdoMet. Manipulation of the 
cycle through increasing the AdoMet concentration in a cell can stimulate the activity of 
PRMT1. Increased activity of PRMT1 would lead to more methylation of PRMT1 
substrates but also to an accumulation of homocysteine, which is toxic for cells. 
Therefore the rate of transformation of homocysteine into methionine has to be increased 
by administrating Betaine to the cells. Betaine is the principal methyl donor for the 
generation of methionine from homocysteine.We provide evidence that AdoMet and 
betaine can correct HCV induced STAT1 hypomethylation. First, treatment of cells that 
express a constitutive active HA-PP2Ac and therefore have hypomethylated STAT1, with 
AdoMet and betaine increases the methylation of STAT1. Second, the administration of 
AdoMet and betaine to cells expressing HCV proteins prior to the stimulation with IFNα 
restores the Jak-STAT signaling. And third, treatment of Huh7 cells haboring a 
subgenomic HCV replicon, a well established model for HCV replication, with IFNα 
inhibits HCV subgenomic RNA replication. By supplementing IFNα  with AdoMet and 
betaine, we could increase the effect of the IFNα about tenfold. Taken together, our 
results suggest the addition of AdoMet and betaine, two nontoxic substances that are 
available in many countries without prescription, to the current standard treatment of 
CHC with pegIFNα and ribavirin could increase the efficacy of the treatment. This 
hypothesis has to be tested in clinical trials.  
 
 
 
 
4.3 Induction of ER stress and the consequences for the cell 
 
The unfolded protein response (UPR) deals with adverse effects of ER stress in a timely 
and efficient manner at the early stage and thus enhances cell survival. But prolonged ER 
stress, induced for example by viral infection, has severe consequences for the cell, 
including apoptosis and disturbed lipid metabolism. For example, to resolve ER stress, 
sustained UPR consumes energy in retrotranslocating unfolded or misfolded proteins 
retained in the ER to the cytoplasm for ubiquitination (128). This energy depletion can 
contribute to programmed cell death (129). The activation of JNK and mitochondria-
dependent caspases during ER stress leads also to apoptosis (130). Another death-
signaling pathway activated by ER stress is mediated by transcriptional activation of 
CHOP, that potentiates apoptosis through repressing expression of anti-apoptotic Bcl2 
and Bcl-XL, and induction of ER oxidase 1α which generates reactive oxygen species and 
depletes reduced glutathione (103). In addition, prolonged ER stress is associated with 
release of ER Ca2+ stores, which can perturb mitochondria, triggering oxidative stress. 
Ca2+-induced oxidative stress can induce both cell death and activate NF-κB signaling, 
contributing to inflammation (131). Aside from cell death and inflammation, ER stress 
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contributes to intracellular lipid accumulation, which is mediated by the ER-associated 
transmembrane sterolresponse element-binding proteins (SREBP) (132). Once activated 
during ER stress, SREBP acts as transcription factors of fatty acids/triglycerides and 
cholesterol, respectively, and cellular uptake of lipoproteins (133). ER stress-induced 
overproduction of lipids can lead to fatty liver (134). 
The UPR triggered by the translation of viral proteins can be viewed as a two edged 
sword. On the one hand, the UPR can promote cell survival, which impairs viral 
eradication. On the other hand, the UPR-induced PERK-mediated translation inhibition 
could suppress viral protein synthesis. It is known that HCV induces components of the 
UPR, a variety of evidence indicates that individual HCV proteins modulate the UPR and 
ER stress response which can result mainly in increased viral replication and failure to 
eliminate infected cells. For instance, NS4B induces ATF6 and IRE1 to favor the HCV 
subreplicon and HCV viral replication (135). The expression of the HCV genes correlates 
with the translocation of the cytoplasmic domain of ATF6 to the nucleus of cells 
harboring HCV subgenomic replicons. Beside of the activation of ATF6, XBP1 spliced 
mRNA and sXBP1 protein levels are elevated in HCV replicon-expressing cells (111), 
but the transactivation activity of sXBP1 is repressed in the HCV-infected cells, which 
prevents the induction of the ER degradation-enhancing-mannosidase-like protein 
(EDEM) (136). HCV infection also modulates protein synthesis through PERK by 
suppressing PERK activity through HCV E2 (112).  In addition, HCV induced ER stress 
results in reduced protein glycosylation, which disrupts the proper folding and assembly 
of MHC class 1 molecules (137). Therefore cells expressing HCV subgenomic replicons 
have lower MHC class 1 cell surface expression and less antigen presentation to 
cytotoxic T lymphocytes. This ER stress-mediated interference of MHC class1 assembly 
and cell surface expression may contribute to the persistence and pathogenesis of HCV 
infection. But it remains to be investigated if these observations reflect of what occurs in 
vivo in HCV-infected patients and if a attenuated UPR contributes to the chronicity of 
viral infection or if the HCV-induced ER stress response promotes the progression to 
apoptosis and inflammation. 
In the present work, we could show that expression of HCV proteins in human 
osteosarcoma cells induce an ER stress response. One result of prolonged ER stress is the 
release of ER Ca2+ stores into the cytosol. Therefore the cytosolic calcium-concentration 
increases for a short time, before the Ca2+ enters other calcium-storage compartments like 
the mitochondria. But these short calcium-transients are enough to activate Ca2+ -
dependent kinases, that phosphorylate the transcription factor CREB. Until now, we 
could not identify the kinase responsible for the phosphorylation of CREB, but one good 
candidate kinase is the Calcium-calmodulin-dependent kinase II, which is known to be 
expressed ubiquitous and which can phosphorylate CREB in a Ca2+- dependent manner. 
However, we could demonstrate with siRNA experiments that CREB is responsible for 
the PP2Ac up regulation. The activated CREB binds to the PP2Ac promoter and activates 
PP2Ac transcription.  
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4.4 Summary 
 
Summarizing all our results, we can draw the following picture (Fig.6). The expression of 
HCV proteins induces an ER stress response. The consequence of prolonged ER stress is 
the release of Ca2+ from the ER into the cytosol. Cytosolic Ca2+-transients activate Ca2+ 
dependent kinases, which phosphorylate the transcription factor CREB. Phosphorylated 
CREB binds to the CRE-element in the PP2Ac promoter and induces transcription.  
Elevated PP2Ac level inhibits the enzymatic activity of PRMT1. Two consequences of 
reduced PRMT1 activity are the hypomethylation of STAT 1 and the hypomethylation of 
NS3 helicase. Hypomethylated STAT1 shows increased association with PIAS1 and 
decreased binding to IFNα-target genes upon IFNα treatment. The consequence of the 
inhibited IFNα-signaling is a reduced antiviral response, which contributes to the 
development of chronic liver infection, which later on can progress to liver cirrhosis and 
HCC. On the other hand, the unwinding activity of hypomethylated NS3 is increased 
compared to methylated NS3. The higher unwinding activty of NS3 causes an increase in 
viral replication. Therefore the upregulation of PP2Ac has two advantages for the virus: 
reduced cellular antiviral response and increased viral replication. 
 
 
 
Fig.6: The consequences of the ER stress induced by HCV. 
The expression of HCV proteins induces ER stress, increased Ca2+ concentrations in the cytosol, 
phosphorylation of CREB and increased PP2Ac transcription. PP2Ac afterwards inhibits the enzymatic 
activity of PRMT1. Two consequences of decreased PRMT1 activity are the inhibition of Jak-STAT 
signaling and the increased activity of NS3 helicase resulting in more HCV replication. 
 
 
 
 
 
 
 
 77 
5. Perspectives 
 
The promising results of the improved IFNα signaling in UHCV 57.3 cells (express HCV 
proteins in the absence of tetracycline) after AdoMet/Betaine treatment and the fact that 
the expression of HBV proteins in Huh7.93 cells induces obviously the same IFNα 
inhibiting mechanism (increased PP2Ac levels, hypomethylated STAT1 and decreased 
induction of IFNα target genes), it opens the interesting perspective of correcting the 
HBV induced defect in IFNα signaling also by treating cells with AdoMet and betaine.  
We would expect, that the AdoMet/betaine treatment would at least partially restore the 
IFNα signaling in Huh7.93 cells and would lead to an increased induction of antiviral 
genes compared to Huh7.93 cells not treated with AdoMet/Betaine. 
 
AdoMet and Betaine are two compounds, which are already on the market as over the 
counter drugs, and which are used to treat liver diseases. Now that we could show 
improved IFNα signaling in UHCV57.3 cell pretreated with AdoMet and betaine,  we 
plan to apply these drugs to HCV patients in a clinical study. The plan is to retreat non-
responders with a combination of AdoMet, Betaine, IFNα and rabavirin.  
 
To increase the activity of PRMT1 by manipulating the methionine/AdoMet cycle is one 
possibility to correct the inhibition of the IFNα signaling by HCV. Another possibility 
would be to target the first event, induction of ER stress by HCV. Without the induction 
of ER stress during expression of HCV proteins, Ca2+ would not leak out of the ER and 
the phosphorylation of CREB would not occur, so the level of PP2A would not rise and 
therefore there would be no inhibition of PRMT1. One possibility to avoid ER stress is 
the treatment of cells with chemical chaperones. Chemical chaperones are a group of 
low-molecular-weight componds, which can reverse the mislocalization and/or 
aggregation of proteins(138).  Polyos such as glycerol, trimethylamines such as 
trimethlyamine N-oxide (TMAO), amino acid derivatives and other compounds like 4-
phenylbutyric acid (PBA) and membrane-permeable forms of enzyme antagonists belong 
to the chemical chaperones. The mechanisms by which chemical chaperones function are 
not fully understood but are thought to include stabilization of improperly folded 
proteins, reduction of aggregation, prevention of nonproductive interactions with other 
resident proteins and alteration of the activity of endogenous chaperones in such a way 
that the affected proteins are more efficiently transported to the appropriate intracellular 
or extracellular destination. 
An interesting experiment would be the expression of viral proteins in UHCV57.3 cells 
for 24h in the presence of chemical chaperones, and check afterwards for the level of 
PP2Ac and for the induction of ER stress markers like BiP or spliced XBP1. We would 
expect, that the increased level of chaperones in the ER prevent the induction of ER-
stress and the Ca2+ -transients in the cytosol. Therefore the transcription factor CREB 
does not get phosphorylated, and the PP2Ac level stays constant even in the presence of 
viral proteins. 
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